Abstract
Neurotrophins (NTs) are members of a neuronal growth factor protein family whose action is mediated by the tropomyosin receptor kinase (TRK) receptor family receptors and the p75 NT receptor (p75NTR), a member of the tumor necrosis factor (TNF) receptor family. Although NTs were first discovered in neurons, recent studies have suggested that NTs and their receptors are expressed in various types of stem cells mediating pivotal signaling events in stem cell biology. The concept of stem cell therapy has already attracted much attention as a potential strategy for the treatment of neurodegenerative diseases (NDs). Strikingly, NTs, proNTs, and their receptors are gaining interest as key regulators of stem cells differentiation, survival, self-renewal, plasticity, and migration. In this review, we elaborate the recent progress in understanding of NTs and their action on various stem cells. First, we provide current knowledge of NTs, proNTs, and their receptor isoforms and signaling pathways. Subsequently, we describe recent advances in the understanding of NT activities in various stem cells and their role in NDs, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD). Finally, we compile the implications of NTs and stem cells from a clinical perspective and discuss the challenges with regard to transplantation therapy for treatment of AD and PD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mowla SJ, Farhadi HF, Pareek S, Atwal JK, Morris SJ, Seidah NG, Murphy RA (2001) Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. J Biol Chem 276(16):12660–12666. doi:10.1074/jbc.M008104200
Reichardt LF (2006) Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 361(1473):1545–1564. doi:10.1098/rstb.2006.1894
Park H, Poo MM (2013) Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 14(1):7–23. doi:10.1038/nrn3379
Edelmann E, Cepeda-Prado E, Franck M, Lichtenecker P, Brigadski T, Lessmann V (2015) Theta burst firing recruits BDNF release and signaling in postsynaptic CA1 neurons in spike-timing-dependent LTP. Neuron 86(4):1041–1054. doi:10.1016/j.neuron.2015.04.007
Cohen S, Levi-Montalcini R, Hamburger V (1954) A nerve growth-stimulating factor isolated from sarcom as 37 and 180. Proc Natl Acad Sci U S A 40(10):1014–1018
Lessmann V, Gottmann K, Malcangio M (2003) Neurotrophin secretion: current facts and future prospects. Prog Neurobiol 69(5):341–374. doi:10.1016/S0301-0082(03)00019-4
Levi-Montalcini R (1987) The nerve growth factor 35 years later. Science 237(4819):1154–1162
Arevalo JC, Wu SH (2006) Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci 63(13):1523–1537. doi:10.1007/s00018-006-6010-1
Hempstead BL (2014) Deciphering proneurotrophin actions. Handb Exp Pharmacol 220:17–32. doi:10.1007/978-3-642-45106-5_2
Nykjaer A, Willnow TE (2012) Sortilin: a receptor to regulate neuronal viability and function. Trends Neurosci 35(4):261–270. doi:10.1016/j.tins.2012.01.003
Willnow TE, Petersen CM, Nykjaer A (2008) VPS10P-domain receptors—regulators of neuronal viability and function. Nat Rev Neurosci 9(12):899–909. doi:10.1038/nrn2516
Gotz R, Koster R, Winkler C, Raulf F, Lottspeich F, Schartl M, Thoenen H (1994) Neurotrophin-6 is a new member of the nerve growth factor family. Nature 372(6503):266–269. doi:10.1038/372266a0
Lai KO, Fu WY, Ip FC, Ip NY (1998) Cloning and expression of a novel neurotrophin, NT-7, from carp. Mol Cell Neurosci 11(1-2):64–76. doi:10.1006/mcne.1998.0666
Nilsson AS, Fainzilber M, Falck P, Ibanez CF (1998) Neurotrophin-7: a novel member of the neurotrophin family from the zebrafish. FEBS Lett 424(3):285–290. doi:10.1016/S0014-5793(98)00192-6
Berkemeier LR, Ozcelik T, Francke U, Rosenthal A (1992) Human chromosome 19 contains the neurotrophin-5 gene locus and three related genes that may encode novel acidic neurotrophins. Somat Cell Mol Genet 18(3):233–245. doi:10.1007/BF01233860
Martin GR (1981) Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A 78(12):7634–7638
Evans MJ, Kaufman MH (1981) Establishment in culture of pluripotential cells from mouse embryos. Nature 292(5819):154–156
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998) Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145–1147
Klimanskaya I, Rosenthal N, Lanza R (2008) Derive and conquer: sourcing and differentiating stem cells for therapeutic applications. Nat Rev Drug Discov 7(2):131–142. doi:10.1038/nrd2403
Goodell MA, Nguyen H, Shroyer N (2015) Somatic stem cell heterogeneity: diversity in the blood, skin and intestinal stem cell compartments. Nat Rev Mol Cell Biol 16(5):299–309. doi:10.1038/nrm3980
Wobus AM, Boheler KR (2005) Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev 85(2):635–678. doi:10.1152/physrev.00054.2003
Zhu Z, Huangfu D (2013) Human pluripotent stem cells: an emerging model in developmental biology. Development 140(4):705–717. doi:10.1242/dev.086165
Rookmaaker MB, Schutgens F, Verhaar MC, Clevers H (2015) Development and application of human adult stem or progenitor cell organoids. Nat Rev Nephrol 11(9):546–554. doi:10.1038/nrneph.2015.118
Li L, Neaves WB (2006) Normal stem cells and cancer stem cells: the niche matters. Cancer Res 66(9):4553–4557. doi:10.1158/0008-5472.CAN-05-3986
Lotem J, Sachs L (2006) Epigenetics and the plasticity of differentiation in normal and cancer stem cells. Oncogene 25(59):7663–7672. doi:10.1038/sj.onc.1209816
Okita K, Yamanaka S (2011) Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc Lond B Biol Sci 366(1575):2198–2207. doi:10.1098/rstb.2011.0016
Yamanaka S (2012) Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 10(6):678–684. doi:10.1016/j.stem.2012.05.005
Tomellini E, Lagadec C, Polakowska R, Le Bourhis X (2014) Role of p75 neurotrophin receptor in stem cell biology: more than just a marker. Cell Mol Life Sci 71(13):2467–2481. doi:10.1007/s00018-014-1564-9
Lu P, Jones LL, Snyder EY, Tuszynski MH (2003) Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Exp Neurol 181(2):115–129. doi:10.1016/S0014-4886(03)00037-2
Pyle AD, Lock LF, Donovan PJ (2006) Neurotrophins mediate human embryonic stem cell survival. Nat Biotechnol 24(3):344–350. doi:10.1038/nbt1189
Levi-Montalcini R, Hamburger V (1953) A diffusible agent of mouse sarcoma, producing hyperplasia of sympathetic ganglia and hyperneurotization of viscera in the chick embryo. J Exp Zool 123(2):233–287. doi:10.1002/jez.1401230203
Cohen S, Levi-Montalcini R (1956) A nerve growth-stimulating factor isolated from snake venom. Proc Natl Acad Sci U S A 42(9):571–574
Tischler AS, Riseberg JC, Hardenbrook MA, Cherington V (1993) Nerve growth factor is a potent inducer of proliferation and neuronal differentiation for adult rat chromaffin cells in vitro. J Neurosci 13(4):1533–1542
Misko TP, Radeke MJ, Shooter EM (1987) Nerve growth factor in neuronal development and maintenance. J Exp Biol 132:177–190
Sofroniew MV, Howe CL, Mobley WC (2001) Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24:1217–1281. doi:10.1146/annurev.neuro.24.1.1217
Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA (1995) Nerve growth factor in Alzheimer’s disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 15(9):6213–6221
Lorigados Pedre L, Pavon Fuentes N, Alvarez Gonzalez L, McRae A, Serrano Sanchez T, Blanco Lescano L, Macias Gonzalez R (2002) Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats. Brain Res 952(1):122–127. doi:10.1016/S0006-8993(02)03222-5
Shamini Ayyadhury BSP, Klaus Heese BSP (2007) Neurotrophins—more than neurotrophic. Curr Immunol Rev 3(3):189–215. doi:10.2174/157339507781483504
Heese K, Inoue N, Sawada T (2006) NF-kappaB regulates B-cell-derived nerve growth factor expression. Cell Mol Immunol 3(1):63–66
Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A (1996) Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 19(11):514–520. doi:10.1016/S0166-2236(96)10058-8
Indo Y (2014) Neurobiology of pain, interoception and emotional response: lessons from nerve growth factor-dependent neurons. Eur J Neurosci 39(3):375–391. doi:10.1111/ejn.12448
Lewin GR, Nykjaer A (2014) Pro-neurotrophins, sortilin, and nociception. Eur J Neurosci 39(3):363–374. doi:10.1111/ejn.12466
Torcia M, Bracci-Laudiero L, Lucibello M et al (1996) Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell 85(3):345–356. doi:10.1016/S0092-8674(00)81113-7
Einarsdottir E, Carlsson A, Minde J et al (2004) A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception. Hum Mol Genet 13(8):799–805. doi:10.1093/hmg/ddh096
Hallbook F (1999) Evolution of the vertebrate neurotrophin and Trk receptor gene families. Curr Opin Neurobiol 9(5):616–621. doi:10.1016/S0959-4388(99)00011-2
Ullrich A, Gray A, Berman C, Dull TJ (1983) Human beta-nerve growth factor gene sequence highly homologous to that of mouse. Nature 303(5920):821–825
Fahnestock M, Yu G, Coughlin MD (2004) ProNGF: a neurotrophic or an apoptotic molecule? Prog Brain Res 146:101–110. doi:10.1016/S0079-6123(03)46007-X
Darling TL, Petrides PE, Beguin P, Frey P, Shooter EM, Selby M, Rutter WJ (1983) The biosynthesis and processing of proteins in the mouse 7S nerve growth factor complex. Cold Spring Harb Symp Quant Biol 48(Pt 1):427–434
Garzon D, Yu G, Fahnestock M (2004) A new brain-derived neurotrophic factor transcript and decrease inbrain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer’s disease parietal cortex. J Neurochem 82(5):1058–1064. doi:10.1046/j.1471-4159.2002.01030.x
Seidah NG, Benjannet S, Pareek S, Chretien M, Murphy RA (1996) Cellular processing of the neurotrophin precursors of NT3 and BDNF by the mammalian proprotein convertases. FEBS Lett 379(3):247–250
Lee R, Kermani P, Teng KK, Hempstead BL (2001) Regulation of cell survival by secreted proneurotrophins. Science 294(5548):1945–1948. doi:10.1126/science.1065057
Fahnestock M, Michalski B, Xu B, Coughlin MD (2001) The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer’s disease. Mol Cell Neurosci 18(2):210–220. doi:10.1006/mcne.2001.1016
Yepes M, Lawrence DA (2004) Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system? Trends Cardiovasc Med 14(5):173–180. doi:10.1016/j.tcm.2004.03.004
Iulita MF, Cuello AC (2014) Nerve growth factor metabolic dysfunction in Alzheimer’s disease and Down syndrome. Trends Pharmacol Sci 35(7):338–348. doi:10.1016/j.tips.2014.04.010
Miranda E, Lomas DA (2006) Neuroserpin: a serpin to think about. Cell Mol Life Sci 63(6):709–722. doi:10.1007/s00018-005-5077-4
Bradshaw RA, Murray-Rust J, Ibanez CF, McDonald NQ, Lapatto R, Blundell TL (1994) Nerve growth factor: structure/function relationships. Protein Sci 3(11):1901–1913. doi:10.1002/pro.5560031102
Bax B, Blundell TL, Murray-Rust J, McDonald NQ (1997) Structure of mouse 7S NGF: a complex of nerve growth factor with four binding proteins. Structure 5(10):1275–1285. doi:10.1016/S0969-2126(97)00280-3
Freund-Michel V, Frossard N (2008) The nerve growth factor and its receptors in airway inflammatory diseases. Pharmacol Ther 117(1):52–76. doi:10.1016/j.pharmthera.2007.07.003
Eibl JK, Strasser BC, Ross GM (2012) Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. Neurochem Int 61(8):1266–1275. doi:10.1016/j.neuint.2012.10.008
Robinson RC, Radziejewski C, Stuart DI, Jones EY (1995) Structure of the brain-derived neurotrophic factor/neurotrophin 3 heterodimer. Biochemistry 34(13):4139–4146
Feng D, Kim T, Ozkan E, Light M, Torkin R, Teng KK, Hempstead BL, Garcia KC (2010) Molecular and structural insight into proNGF engagement of p75NTR and sortilin. J Mol Biol 396(4):967–984. doi:10.1016/j.jmb.2009.12.030
Barde YA, Edgar D, Thoenen H (1982) Purification of a new neurotrophic factor from mammalian brain. EMBO J 1(5):549–553
Barde YA, Davies AM, Johnson JE, Lindsay RM, Thoenen H (1987) Brain derived neurotrophic factor. Prog Brain Res 71:185–189
Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, Thoenen H, Barde YA (1989) Molecular cloning and expression of brain-derived neurotrophic factor. Nature 341(6238):149–152. doi:10.1038/341149a0
Cohen-Cory S, Kidane AH, Shirkey NJ, Marshak S (2010) Brain-derived neurotrophic factor and the development of structural neuronal connectivity. Dev Neurobiol 70(5):271–288. doi:10.1002/dneu.20774
Nagahara AH, Tuszynski MH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10(3):209–219. doi:10.1038/nrd3366
Ohira K, Hayashi M (2009) A new aspect of the TrkB signaling pathway in neural plasticity. Curr Neuropharmacol 7(4):276–285. doi:10.2174/157015909790031210
Zuccato C, Cattaneo E (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5(6):311–322. doi:10.1038/nrneurol.2009.54
Angelucci F, Brene S, Mathe AA (2005) BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 10(4):345–352. doi:10.1038/sj.mp.4001637
Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R (2014) Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci 8:430. doi:10.3389/fncel.2014.00430
Prakash YS, Martin RJ (2014) Brain-derived neurotrophic factor in the airways. Pharmacol Ther 143(1):74–86. doi:10.1016/j.pharmthera.2014.02.006
Lee DH, Geyer E, Flach AC, Jung K, Gold R, Flugel A, Linker RA, Luhder F (2012) Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol 123(2):247–258. doi:10.1007/s00401-011-0890-3
Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T (2007) Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 90(3):397–406. doi:10.1016/j.ygeno.2007.05.004
Negro A, Tavella A, Grandi C, Skaper SD (1994) Production and characterization of recombinant rat brain-derived neurotrophic factor and neurotrophin-3 from insect cells. J Neurochem 62(2):471–478
Harte-Hargrove LC, Maclusky NJ, Scharfman HE (2013) Brain-derived neurotrophic factor-estrogen interactions in the hippocampal mossy fiber pathway: implications for normal brain function and disease. Neuroscience 239:46–66. doi:10.1016/j.neuroscience.2012.12.029
Mowla SJ, Pareek S, Farhadi HF et al (1999) Differential sorting of nerve growth factor and brain-derived neurotrophic factor in hippocampal neurons. J Neurosci 19(6):2069–2080
Faria RS, Sartori CR, Canova F, Ferrari EA (2013) Classical aversive conditioning induces increased expression of mature-BDNF in the hippocampus and amygdala of pigeons. Neuroscience 255:122–133. doi:10.1016/j.neuroscience.2013.09.054
Carlino D, De Vanna M, Tongiorgi E (2013) Is altered BDNF biosynthesis a general feature in patients with cognitive dysfunctions? Neuroscientist 19(4):345–353. doi:10.1177/1073858412469444
Nagappan G, Zaitsev E, Senatorov VV Jr, Yang J, Hempstead BL, Lu B (2009) Control of extracellular cleavage of ProBDNF by high frequency neuronal activity. Proc Natl Acad Sci U S A 106(4):1267–1272. doi:10.1073/pnas.0807322106
Pang PT, Teng HK, Zaitsev E et al (2004) Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 306(5695):487–491. doi:10.1126/science.1100135
Robinson RC, Radziejewski C, Spraggon G et al (1999) The structures of the neurotrophin 4 homodimer and the brain-derived neurotrophic factor/neurotrophin 4 heterodimer reveal a common Trk-binding site. Protein Sci 8(12):2589–2597. doi:10.1110/ps.8.12.2589
Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, Yancopoulos GD (1990) Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science 247(4949 Pt 1):1446–1451
Chalazonitis A (1996) Neurotrophin-3 as an essential signal for the developing nervous system. Mol Neurobiol 12(1):39–53. doi:10.1007/BF02740746
Maisonpierre PC, Le Beau MM, Espinosa R 3rd et al (1991) Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 10(3):558–568
Chalazonitis A (2004) Neurotrophin-3 in the development of the enteric nervous system. Prog Brain Res 146:243–263. doi:10.1016/S0079-6123(03)46016-0
Bates B, Rios M, Trumpp A, Chen C, Fan G, Bishop JM, Jaenisch R (1999) Neurotrophin-3 is required for proper cerebellar development. Nat Neurosci 2(2):115–117. doi:10.1038/5669
Lykissas MG, Batistatou AK, Charalabopoulos KA, Beris AE (2007) The role of neurotrophins in axonal growth, guidance, and regeneration. Curr Neurovasc Res 4(2):143–151
Roh J, Muelleman T, Tawfik O, Thomas SM (2015) Perineural growth in head and neck squamous cell carcinoma: a review. Oral Oncol 51(1):16–23. doi:10.1016/j.oraloncology.2014.10.004
Tauszig-Delamasure S, Bouzas-Rodriguez J (2011) Targeting neurotrophin-3 and its dependence receptor tyrosine kinase receptor C: a new antitumoral strategy. Expert Opin Ther Targets 15(7):847–858. doi:10.1517/14728222.2011.575361
Yano H, Torkin R, Martin LA, Chao MV, Teng KK (2009) Proneurotrophin-3 is a neuronal apoptotic ligand: evidence for retrograde-directed cell killing. J Neurosci 29(47):14790–14802. doi:10.1523/JNEUROSCI.2059-09.2009
Farhadi HF, Mowla SJ, Petrecca K, Morris SJ, Seidah NG, Murphy RA (2000) Neurotrophin-3 sorts to the constitutive secretory pathway of hippocampal neurons and is diverted to the regulated secretory pathway by coexpression with brain-derived neurotrophic factor. J Neurosci 20(11):4059–4068
Butte MJ, Hwang PK, Mobley WC, Fletterick RJ (1998) Crystal structure of neurotrophin-3 homodimer shows distinct regions are used to bind its receptors. Biochemistry 37(48):16846–16852. doi:10.1021/bi981254o
Ibanez CF (1996) Neurotrophin-4: the odd one out in the neurotrophin family. Neurochem Res 21(7):787–793
Berkemeier LR, Winslow JW, Kaplan DR, Nikolics K, Goeddel DV, Rosenthal A (1991) Neurotrophin-5: a novel neurotrophic factor that activates trk and trkB. Neuron 7(5):857–866
Koliatsos VE, Cayouette MH, Berkemeier LR, Clatterbuck RE, Price DL, Rosenthal A (1994) Neurotrophin 4/5 is a trophic factor for mammalian facial motor neurons. Proc Natl Acad Sci U S A 91(8):3304–3308
Zheng JL, Stewart RR, Gao WQ (1995) Neurotrophin-4/5 enhances survival of cultured spiral ganglion neurons and protects them from cisplatin neurotoxicity. J Neurosci 15(7 Pt 2):5079–5087
Cohen A, Bray GM, Aguayo AJ (1994) Neurotrophin-4/5 (NT-4/5) increases adult rat retinal ganglion cell survival and neurite outgrowth in vitro. J Neurobiol 25(8):953–959. doi:10.1002/neu.480250805
Hondermarck H (2012) Neurotrophins and their receptors in breast cancer. Cytokine Growth Factor Rev 23(6):357–365. doi:10.1016/j.cytogfr.2012.06.004
Szczepankiewicz A, Rachel M, Sobkowiak P, Kycler Z, Wojsyk-Banaszak I, Schoneich N, Skibinska M, Breborowicz A (2012) Serum neurotrophin-3 and neurotrophin-4 levels are associated with asthma severity in children. Eur Respir J 39(4):1035–1037. doi:10.1183/09031936.00136611
Aven L, Paez-Cortez J, Achey R, Krishnan R, Ram-Mohan S, Cruikshank WW, Fine A, Ai X (2014) An NT4/TrkB-dependent increase in innervation links early-life allergen exposure to persistent airway hyperreactivity. FASEB J 28(2):897–907. doi:10.1096/fj.13-238212
Grewe M, Vogelsang K, Ruzicka T, Stege H, Krutmann J (2000) Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. J Investig Dermatol 114(6):1108–1112. doi:10.1046/j.1523-1747.2000.00974.x
Kanda N, Koike S, Watanabe S (2005) Prostaglandin E2 enhances neurotrophin-4 production via EP3 receptor in human keratinocytes. J Pharmacol Exp Ther 315(2):796–804. doi:10.1124/jpet.105.091645
Yoshizaki K, Yamamoto S, Yamada A et al (2008) Neurotrophic factor neurotrophin-4 regulates ameloblastin expression via full-length TrkB. J Biol Chem 283(6):3385–3391. doi:10.1074/jbc.M704913200
Wiesmann C, Ultsch MH, Bass SH, de Vos AM (1999) Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature 401(6749):184–188. doi:10.1038/43705
Greco A, Villa R, Pierotti MA (1996) Genomic organization of the human NTRK1 gene. Oncogene 13(11):2463–2466
Barker PA, Lomen-Hoerth C, Gensch EM, Meakin SO, Glass DJ, Shooter EM (1993) Tissue-specific alternative splicing generates two isoforms of the trkA receptor. J Biol Chem 268(20):15150–15157
Tacconelli A, Farina AR, Cappabianca L et al (2004) TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 6(4):347–360. doi:10.1016/j.ccr.2004.09.011
Meakin SO, Gryz EA, MacDonald JI (1997) A kinase insert isoform of rat TrkA supports nerve growth factor-dependent cell survival but not neurite outgrowth. J Neurochem 69(3):954–967
Dubus P, Parrens M, El-Mokhtari Y, Ferrer J, Groppi A, Merlio JP (2000) Identification of novel trkA variants with deletions in leucine-rich motifs of the extracellular domain. J Neuroimmunol 107(1):42–49
Jullien J, Guili V, Reichardt LF, Rudkin BB (2002) Molecular kinetics of nerve growth factor receptor trafficking and activation. J Biol Chem 277(41):38700–38708. doi:10.1074/jbc.M202348200
Zhou J, Valletta JS, Grimes ML, Mobley WC (1995) Multiple levels for regulation of TrkA in PC12 cells by nerve growth factor. J Neurochem 65(3):1146–1156
Marlin MC, Li G (2015) Biogenesis and function of the NGF/TrkA signaling endosome. Int Rev Cell Mol Biol 314:239–257. doi:10.1016/bs.ircmb.2014.10.002
Ultsch MH, Wiesmann C, Simmons LC, Henrich J, Yang M, Reilly D, Bass SH, de Vos AM (1999) Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and TrkC. J Mol Biol 290(1):149–159. doi:10.1006/jmbi.1999.2816
Urfer R, Tsoulfas P, O’Connell L, Hongo JA, Zhao W, Presta LG (1998) High resolution mapping of the binding site of TrkA for nerve growth factor and TrkC for neurotrophin-3 on the second immunoglobulin-like domain of the Trk receptors. J Biol Chem 273(10):5829–5840
Bertrand T, Kothe M, Liu J et al (2012) The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition. J Mol Biol 423(3):439–453. doi:10.1016/j.jmb.2012.08.002
Nikoletopoulou V, Lickert H, Frade JM, Rencurel C, Giallonardo P, Zhang L, Bibel M, Barde YA (2010) Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not. Nature 467(7311):59–63. doi:10.1038/nature09336
Soppet D, Escandon E, Maragos J et al (1991) The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell 65(5):895–903
Slaugenhaupt SA, Blumenfeld A, Liebert CB et al (1995) The human gene for neurotrophic tyrosine kinase receptor type 2 (NTRK2) is located on chromosome 9 but is not the familial dysautonomia gene. Genomics 25(3):730–732
Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24:677–736. doi:10.1146/annurev.neuro.24.1.677
Ninkina N, Grashchuck M, Buchman VL, Davies AM (1997) TrkB variants with deletions in the leucine-rich motifs of the extracellular domain. J Biol Chem 272(20):13019–13025
Baxter GT, Radeke MJ, Kuo RC et al (1997) Signal transduction mediated by the truncated trkB receptor isoforms, trkB.T1 and trkB.T2. J Neurosci 17(8):2683–2690
Stoilov P, Castren E, Stamm S (2002) Analysis of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism. Biochem Biophys Res Commun 290(3):1054–1065. doi:10.1006/bbrc.2001.6301
Forooghian F, Kojic L, Gu Q, Prasad SS (2001) Identification of a novel truncated isoform of trkB in the kitten primary visual cortex. J Mol Neurosci 17(1):81–88. doi:10.1385/JMN:17:1:81
Barbacid M (1995) Neurotrophic factors and their receptors. Curr Opin Cell Biol 7(2):148–155
Feng Y, Vetro A, Kiss E et al (2008) Association of the neurotrophic tyrosine kinase receptor 3 (NTRK3) gene and childhood-onset mood disorders. Am J Psychiatry 165(5):610–616. doi:10.1176/appi.ajp.2007.07050805
Lamballe F, Klein R, Barbacid M (1991) trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 66(5):967–979
Lamballe F, Tapley P, Barbacid M (1993) trkC encodes multiple neurotrophin-3 receptors with distinct biological properties and substrate specificities. EMBO J 12(8):3083–3094
Valenzuela DM, Maisonpierre PC, Glass DJ et al (1993) Alternative forms of rat TrkC with different functional capabilities. Neuron 10(5):963–974
Tsoulfas P, Soppet D, Escandon E, Tessarollo L, Mendoza-Ramirez JL, Rosenthal A, Nikolics K, Parada LF (1993) The rat trkC locus encodes multiple neurogenic receptors that exhibit differential response to neurotrophin-3 in PC12 cells. Neuron 10(5):975–990
Radeke MJ, Misko TP, Hsu C, Herzenberg LA, Shooter EM (1987) Gene transfer and molecular cloning of the rat nerve growth factor receptor. Nature 325(6105):593–597. doi:10.1038/325593a0
Huebner K, Isobe M, Chao M et al (1986) The nerve growth-factor receptor gene is at human-chromosome region 17q12-17q22, distal to the chromosome-17 breakpoint in acute leukemias. Proc Natl Acad Sci U S A 83(5):1403–1407. doi:10.1073/pnas.83.5.1403
Chao MV (2003) Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 4(4):299–309. doi:10.1038/nrn1078
Kraemer BR, Yoon SO, Carter BD (2014) The biological functions and signaling mechanisms of the p75 neurotrophin receptor. Handb Exp Pharmacol 220:121–164. doi:10.1007/978-3-642-45106-5_6
Barrett GL (2000) The p75 neurotrophin receptor and neuronal apoptosis. Prog Neurobiol 61(2):205–229. doi:10.1016/S0301-0082(99)00056-8
von Schack D, Casademunt E, Schweigreiter R, Meyer M, Bibel M, Dechant G (2001) Complete ablation of the neurotrophin receptor p75NTR causes defects both in the nervous and the vascular system. Nat Neurosci 4(10):977–978. doi:10.1038/nn730
Lee KF, Li E, Huber LJ, Landis SC, Sharpe AH, Chao MV, Jaenisch R (1992) Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. Cell 69(5):737–749
Poser R, Dokter M, von Bohlen Und Halbach V, Berger SM, Busch R, Baldus M, Unsicker K, von Bohlen Und Halbach O (2015) Impact of a deletion of the full-length and short isoform of p75NTR on cholinergic innervation and the population of postmitotic doublecortin positive cells in the dentate gyrus. Front Neuroanat 9:63. doi:10.3389/fnana.2015.00063
Sabry MA, Fares M, Folkesson R, Al-Ramadan M, Alabkal J, Al-Kafaji G, Hassan M (2016) Commentary: Impact of a deletion of the full-length and short isoform of p75NTR on cholinergic innervation and the population of postmitotic doublecortin positive cells in the dentate gyrus. Front Neuroanat 10:14. doi:10.3389/fnana.2016.00014
Langevin C, Jaaro H, Bressanelli S, Fainzilber M, Tuffereau C (2002) Rabies virus glycoprotein (RVG) is a trimeric ligand for the N-terminal cysteine-rich domain of the mammalian p75 neurotrophin receptor. J Biol Chem 277(40):37655–37662. doi:10.1074/jbc.M201374200
Dechant G, Barde YA (2002) The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat Neurosci 5(11):1131–1136. doi:10.1038/nn1102-1131
Nykjaer A, Lee R, Teng KK et al (2004) Sortilin is essential for proNGF-induced neuronal cell death. Nature 427(6977):843–848. doi:10.1038/nature02319
Grob PM, Ross AH, Koprowski H, Bothwell M (1985) Characterization of the human melanoma nerve growth factor receptor. J Biol Chem 260(13):8044–8049
Gong Y, Cao P, Yu HJ, Jiang T (2008) Crystal structure of the neurotrophin-3 and p75NTR symmetrical complex. Nature 454(7205):789–793. doi:10.1038/nature07089
Mahan AL, Ressler KJ (2012) Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder. Trends Neurosci 35(1):24–35. doi:10.1016/j.tins.2011.06.007
Skaper SD (2012) The neurotrophin family of neurotrophic factors: an overview. Methods Mol Biol 846:1–12. doi:10.1007/978-1-61779-536-7_1
Deinhardt K, Chao MV (2014) Trk receptors. Handb Exp Pharmacol 220:103–119. doi:10.1007/978-3-642-45106-5_5
Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378(6559):785–789. doi:10.1038/378785a0
Bhat RV, Shanley J, Correll MP, Fieles WE, Keith RA, Scott CW, Lee CM (2000) Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A 97(20):11074–11079. doi:10.1073/pnas.190297597
Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65(4):391–426
Vaillant AR, Mazzoni I, Tudan C, Boudreau M, Kaplan DR, Miller FD (1999) Depolarization and neurotrophins converge on the phosphatidylinositol 3-kinase-Akt pathway to synergistically regulate neuronal survival. J Cell Biol 146(5):955–966
Besset V, Scott RP, Ibanez CF (2000) Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J Biol Chem 275(50):39159–39166. doi:10.1074/jbc.M006908200
Auer M, Hausott B, Klimaschewski L (2011) Rho GTPases as regulators of morphological neuroplasticity. Ann Anat 193(4):259–266. doi:10.1016/j.aanat.2011.02.015
Hall A, Lalli G (2010) Rho and Ras GTPases in axon growth, guidance, and branching. Cold Spring Harb Perspect Biol 2(2):a001818. doi:10.1101/cshperspect.a001818
Govek EE, Newey SE, Van Aelst L (2005) The role of the Rho GTPases in neuronal development. Genes Dev 19(1):1–49. doi:10.1101/gad.1256405
Khodosevich K, Monyer H (2010) Signaling involved in neurite outgrowth of postnatally born subventricular zone neurons in vitro. BMC Neurosci 11:18. doi:10.1186/1471-2202-11-18
Schwamborn JC, Puschel AW (2004) The sequential activity of the GTPases Rap1B and Cdc42 determines neuronal polarity. Nat Neurosci 7(9):923–929. doi:10.1038/nn1295
Schwartz M (2004) Rho signalling at a glance. J Cell Sci 117(Pt 23):5457–5458. doi:10.1242/jcs.01582
Chen C, Wirth A, Ponimaskin E (2012) Cdc42: an important regulator of neuronal morphology. Int J Biochem Cell Biol 44(3):447–451. doi:10.1016/j.biocel.2011.11.022
Azzarelli R, Kerloch T, Pacary E (2014) Regulation of cerebral cortex development by Rho GTPases: insights from in vivo studies. Front Cell Neurosci 8:445. doi:10.3389/fncel.2014.00445
Nishimura T, Yamaguchi T, Kato K, Yoshizawa M, Nabeshima Y, Ohno S, Hoshino M, Kaibuchi K (2005) PAR-6-PAR-3 mediates Cdc42-induced Rac activation through the Rac GEFs STEF/Tiam1. Nat Cell Biol 7(3):270–277. doi:10.1038/ncb1227
Shepherd TR, Hard RL, Murray AM, Pei D, Fuentes EJ (2011) Distinct ligand specificity of the Tiam1 and Tiam2 PDZ domains. Biochemistry 50(8):1296–1308. doi:10.1021/bi1013613
Watabe-Uchida M, John KA, Janas JA, Newey SE, Van Aelst L (2006) The Rac activator DOCK7 regulates neuronal polarity through local phosphorylation of stathmin/Op18. Neuron 51(6):727–739. doi:10.1016/j.neuron.2006.07.020
Ng J, Luo L (2004) Rho GTPases regulate axon growth through convergent and divergent signaling pathways. Neuron 44(5):779–793. doi:10.1016/j.neuron.2004.11.014
Yamaguchi Y, Katoh H, Yasui H, Mori K, Negishi M (2001) RhoA inhibits the nerve growth factor-induced Rac1 activation through Rho-associated kinase-dependent pathway. J Biol Chem 276(22):18977–18983. doi:10.1074/jbc.M100254200
Nusser N, Gosmanova E, Zheng Y, Tigyi G (2002) Nerve growth factor signals through TrkA, phosphatidylinositol 3-kinase, and Rac1 to inactivate RhoA during the initiation of neuronal differentiation of PC12 cells. J Biol Chem 277(39):35840–35846. doi:10.1074/jbc.M203617200
Arakawa Y, Bito H, Furuyashiki T et al (2003) Control of axon elongation via an SDF-1alpha/Rho/mDia pathway in cultured cerebellar granule neurons. J Cell Biol 161(2):381–391. doi:10.1083/jcb.200210149
Shirazi Fard S, Kele J, Vilar M, Paratcha G, Ledda F (2010) Tiam1 as a signaling mediator of nerve growth factor-dependent neurite outgrowth. PLoS One 5(3), e9647. doi:10.1371/journal.pone.0009647
Zhou P, Porcionatto M, Pilapil M et al (2007) Polarized signaling endosomes coordinate BDNF-induced chemotaxis of cerebellar precursors. Neuron 55(1):53–68. doi:10.1016/j.neuron.2007.05.030
Lambert JM, Lambert QT, Reuther GW, Malliri A, Siderovski DP, Sondek J, Collard JG, Der CJ (2002) Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol 4(8):621–625. doi:10.1038/ncb833
Kuruvilla R, Ye H, Ginty DD (2000) Spatially and functionally distinct roles of the PI3-K effector pathway during NGF signaling in sympathetic neurons. Neuron 27(3):499–512
Zhou Y, Lu TJ, Xiong ZQ (2009) NGF-dependent retrograde signaling: survival versus death. Cell Res 19(5):525–526. doi:10.1038/cr.2009.47
Niewiadomska G, Mietelska-Porowska A, Mazurkiewicz M (2011) The cholinergic system, nerve growth factor and the cytoskeleton. Behav Brain Res 221(2):515–526. doi:10.1016/j.bbr.2010.02.024
Madziar B, Shah S, Brock M et al (2008) Nerve growth factor regulates the expression of the cholinergic locus and the high-affinity choline transporter via the Akt/PKB signaling pathway. J Neurochem 107(5):1284–1293. doi:10.1111/j.1471-4159.2008.05681.x
Markus A, Zhong J, Snider WD (2002) Raf and akt mediate distinct aspects of sensory axon growth. Neuron 35(1):65–76
Deckwerth TL, Elliott JL, Knudson CM, Johnson EM Jr, Snider WD, Korsmeyer SJ (1996) BAX is required for neuronal death after trophic factor deprivation and during development. Neuron 17(3):401–411
Lentz SI, Knudson CM, Korsmeyer SJ, Snider WD (1999) Neurotrophins support the development of diverse sensory axon morphologies. J Neurosci 19(3):1038–1048
Liu RY, Snider WD (2001) Different signaling pathways mediate regenerative versus developmental sensory axon growth. J Neurosci 21(17):RC164
Namikawa K, Honma M, Abe K et al (2000) Akt/protein kinase B prevents injury-induced motoneuron death and accelerates axonal regeneration. J Neurosci 20(8):2875–2886
Culmsee C, Gerling N, Lehmann M, Nikolova-Karakashian M, Prehn JH, Mattson MP, Krieglstein J (2002) Nerve growth factor survival signaling in cultured hippocampal neurons is mediated through TrkA and requires the common neurotrophin receptor P75. Neuroscience 115(4):1089–1108
Graef IA, Mermelstein PG, Stankunas K, Neilson JR, Deisseroth K, Tsien RW, Crabtree GR (1999) L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons. Nature 401(6754):703–708. doi:10.1038/44378
Kim MS, Shutov LP, Gnanasekaran A, Lin Z, Rysted JE, Ulrich JD, Usachev YM (2014) Nerve growth factor (NGF) regulates activity of nuclear factor of activated T-cells (NFAT) in neurons via the phosphatidylinositol 3-kinase (PI3K)-Akt-glycogen synthase kinase 3beta (GSK3beta) pathway. J Biol Chem 289(45):31349–31360. doi:10.1074/jbc.M114.587188
Bazenet CE, Mota MA, Rubin LL (1998) The small GTP-binding protein Cdc42 is required for nerve growth factor withdrawal-induced neuronal death. Proc Natl Acad Sci U S A 95(7):3984–3989
Rosario M, Franke R, Bednarski C, Birchmeier W (2007) The neurite outgrowth multiadaptor RhoGAP, NOMA-GAP, regulates neurite extension through SHP2 and Cdc42. J Cell Biol 178(3):503–516. doi:10.1083/jcb.200609146
Da Silva JS, Medina M, Zuliani C, Di Nardo A, Witke W, Dotti CG (2003) RhoA/ROCK regulation of neuritogenesis via profilin IIa-mediated control of actin stability. J Cell Biol 162(7):1267–1279. doi:10.1083/jcb.200304021
Brunet A, Datta SR, Greenberg ME (2001) Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 11(3):297–305. doi:10.1016/S0959-4388(00)00211-7
Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286(5443):1358–1362. doi:10.1126/science.286.5443.1358
Mullen LM, Pak KK, Chavez E, Kondo K, Brand Y, Ryan AF (2012) Ras/p38 and PI3K/Akt but not Mek/Erk signaling mediate BDNF-induced neurite formation on neonatal cochlear spiral ganglion explants. Brain Res 1430:25–34. doi:10.1016/j.brainres.2011.10.054
Kumar V, Zhang MX, Swank MW, Kunz J, Wu GY (2005) Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci 25(49):11288–11299. doi:10.1523/JNEUROSCI.2284-05.2005
Jaworski J, Spangler S, Seeburg DP, Hoogenraad CC, Sheng M (2005) Control of dendritic arborization by the phosphoinositide-3′-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci 25(49):11300–11312. doi:10.1523/JNEUROSCI.2270-05.2005
Nakazawa T, Tamai M, Mori N (2002) Brain-derived neurotrophic factor prevents axotomized retinal ganglion cell death through MAPK and PI3K signaling pathways. Invest Ophthalmol Vis Sci 43(10):3319–3326
Hetman M, Cavanaugh JE, Kimelman D, Xia Z (2000) Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci 20(7):2567–2574
Miller JR, Moon RT (1996) Signal transduction through beta-catenin and specification of cell fate during embryogenesis. Genes Dev 10(20):2527–2539
Hetman M, Hsuan SL, Habas A, Higgins MJ, Xia Z (2002) ERK1/2 antagonizes glycogen synthase kinase-3beta-induced apoptosis in cortical neurons. J Biol Chem 277(51):49577–49584. doi:10.1074/jbc.M111227200
Hetman M, Kanning K, Cavanaugh JE, Xia Z (1999) Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J Biol Chem 274(32):22569–22580. doi:10.1074/jbc.274.32.22569
Cohen P, Goedert M (2004) GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3(6):479–487. doi:10.1038/nrd1415
Davies AM, Horton A, Burton LE, Schmelzer C, Vandlen R, Rosenthal A (1993) Neurotrophin-4/5 is a mammalian-specific survival factor for distinct populations of sensory neurons. J Neurosci 13(11):4961–4967
Minichiello L, Casagranda F, Tatche RS, Stucky CL, Postigo A, Lewin GR, Davies AM, Klein R (1998) Point mutation in trkB causes loss of NT4-dependent neurons without major effects on diverse BDNF responses. Neuron 21(2):335–345
Vadodaria KC, Brakebusch C, Suter U, Jessberger S (2013) Stage-specific functions of the small Rho GTPases Cdc42 and Rac1 for adult hippocampal neurogenesis. J Neurosci 33(3):1179–1189. doi:10.1523/JNEUROSCI.2103-12.2013
Luikart BW, Zhang W, Wayman GA, Kwon CH, Westbrook GL, Parada LF (2008) Neurotrophin-dependent dendritic filopodial motility: a convergence on PI3K signaling. J Neurosci 28(27):7006–7012. doi:10.1523/JNEUROSCI.0195-08.2008
Liot G, Gabriel C, Cacquevel M, Ali C, MacKenzie ET, Buisson A, Vivien D (2004) Neurotrophin-3-induced PI-3 kinase/Akt signaling rescues cortical neurons from apoptosis. Exp Neurol 187(1):38–46. doi:10.1016/j.expneurol.2004.01.002
Kobayashi M, Matsuoka I (2000) Enhancement of sympathetic neuron survival by synergistic action of NT3 and GDNF. Neuroreport 11(11):2541–2545
Airaksinen MS, Saarma M (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3(5):383–394. doi:10.1038/nrn812
Funahashi Y, Namba T, Nakamuta S, Kaibuchi K (2014) Neuronal polarization in vivo: Growing in a complex environment. Curr Opin Neurobiol 27:215–223. doi:10.1016/j.conb.2014.04.009
Okada N, Wada K, Goldsmith BA, Koizumi S (1996) SHP-2 is involved in neurotrophin signaling. Biochem Biophys Res Commun 229(2):607–611. doi:10.1006/bbrc.1996.1851
Easton JB, Royer AR, Middlemas DS (2006) The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor. J Neurochem 97(3):834–845. doi:10.1111/j.1471-4159.2006.03789.x
Goldsmith BA, Koizumi S (1997) Transient association of the phosphotyrosine phosphatase SHP-2 with TrkA is induced by nerve growth factor. J Neurochem 69(3):1014–1019
Dance M, Montagner A, Salles JP, Yart A, Raynal P (2008) The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal 20(3):453–459. doi:10.1016/j.cellsig.2007.10.002
Uren RT, Turnley AM (2014) Regulation of neurotrophin receptor (Trk) signaling: suppressor of cytokine signaling 2 (SOCS2) is a new player. Front Mol Neurosci 7:39. doi:10.3389/fnmol.2014.00039
Arevalo JC, Yano H, Teng KK, Chao MV (2004) A unique pathway for sustained neurotrophin signaling through an ankyrin-rich membrane-spanning protein. EMBO J 23(12):2358–2368. doi:10.1038/sj.emboj.7600253
Feng GS (2007) Shp2-mediated molecular signaling in control of embryonic stem cell self-renewal and differentiation. Cell Res 17(1):37–41. doi:10.1038/sj.cr.7310140
Shen Y, Inoue N, Heese K (2010) Neurotrophin-4 (ntf4) mediates neurogenesis in mouse embryonic neural stem cells through the inhibition of the signal transducer and activator of transcription-3 (stat3) and the modulation of the activity of protein kinase B. Cell Mol Neurobiol 30(6):909–916. doi:10.1007/s10571-010-9520-1
Miranda C, Fumagalli T, Anania MC, Vizioli MG, Pagliardini S, Pierotti MA, Greco A (2010) Role of STAT3 in in vitro transformation triggered by TRK oncogenes. PLoS One 5(3), e9446. doi:10.1371/journal.pone.0009446
Yamauchi J, Miyamoto Y, Tanoue A, Shooter EM, Chan JR (2005) Ras activation of a Rac1 exchange factor, Tiam1, mediates neurotrophin-3-induced Schwann cell migration. Proc Natl Acad Sci U S A 102(41):14889–14894. doi:10.1073/pnas.0507125102
Yamauchi J, Chan JR, Miyamoto Y, Tsujimoto G, Shooter EM (2005) The neurotrophin-3 receptor TrkC directly phosphorylates and activates the nucleotide exchange factor Dbs to enhance Schwann cell migration. Proc Natl Acad Sci U S A 102(14):5198–5203. doi:10.1073/pnas.0501160102
Cherfils J (2014) GEFs and GAPs: mechanisms and structures. In: Ras superfamily small G proteins: biology and mechanisms 1. Springer, pp 51–63
Cherfils J, Zeghouf M (2013) Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiol Rev 93(1):269–309. doi:10.1152/physrev.00003.2012
Yamauchi J, Chan JR, Shooter EM (2003) Neurotrophin 3 activation of TrkC induces Schwann cell migration through the c-Jun N-terminal kinase pathway. Proc Natl Acad Sci U S A 100(24):14421–14426. doi:10.1073/pnas.2336152100
Newbern JM, Li X, Shoemaker SE et al (2011) Specific functions for ERK/MAPK signaling during PNS development. Neuron 69(1):91–105. doi:10.1016/j.neuron.2010.12.003
Watson FL, Heerssen HM, Bhattacharyya A, Klesse L, Lin MZ, Segal RA (2001) Neurotrophins use the Erk5 pathway to mediate a retrograde survival response. Nat Neurosci 4(10):981–988. doi:10.1038/nn720
Finegan KG, Wang X, Lee EJ, Robinson AC, Tournier C (2009) Regulation of neuronal survival by the extracellular signal-regulated protein kinase 5. Cell Death Differ 16(5):674–683. doi:10.1038/cdd.2008.193
Morooka T, Nishida E (1998) Requirement of p38 mitogen-activated protein kinase for neuronal differentiation in PC12 cells. J Biol Chem 273(38):24285–24288
Vaudry D, Stork PJ, Lazarovici P, Eiden LE (2002) Signaling pathways for PC12 cell differentiation: making the right connections. Science 296(5573):1648–1649. doi:10.1126/science.1071552
Li Y, Holtzman DM, Kromer LF, Kaplan DR, Chua-Couzens J, Clary DO, Knusel B, Mobley WC (1995) Regulation of TrkA and ChAT expression in developing rat basal forebrain: evidence that both exogenous and endogenous NGF regulate differentiation of cholinergic neurons. J Neurosci 15(4):2888–2905
Lu B, Pang PT, Woo NH (2005) The yin and yang of neurotrophin action. Nat Rev Neurosci 6(8):603–614. doi:10.1038/nrn1726
Nagappan G, Lu B (2005) Activity-dependent modulation of the BDNF receptor TrkB: mechanisms and implications. Trends Neurosci 28(9):464–471. doi:10.1016/j.tins.2005.07.003
Ortega JA, Alcantara S (2010) BDNF/MAPK/ERK-induced BMP7 expression in the developing cerebral cortex induces premature radial glia differentiation and impairs neuronal migration. Cereb Cortex 20(9):2132–2144. doi:10.1093/cercor/bhp275
Cheng A, Coksaygan T, Tang H, Khatri R, Balice-Gordon RJ, Rao MS, Mattson MP (2007) Truncated tyrosine kinase B brain-derived neurotrophic factor receptor directs cortical neural stem cells to a glial cell fate by a novel signaling mechanism. J Neurochem 100(6):1515–1530. doi:10.1111/j.1471-4159.2006.04337.x
Alonso M, Medina JH, Pozzo-Miller L (2004) ERK1/2 activation is necessary for BDNF to increase dendritic spine density in hippocampal CA1 pyramidal neurons. Learn Mem 11(2):172–178. doi:10.1101/lm.67804
Gottschalk WA, Jiang H, Tartaglia N, Feng L, Figurov A, Lu B (1999) Signaling mechanisms mediating BDNF modulation of synaptic plasticity in the hippocampus. Learn Mem 6(3):243–256
Fritsch B, Reis J, Martinowich K, Schambra HM, Ji Y, Cohen LG, Lu B (2010) Direct current stimulation promotes BDNF-dependent synaptic plasticity: potential implications for motor learning. Neuron 66(2):198–204. doi:10.1016/j.neuron.2010.03.035
Bramham CR, Messaoudi E (2005) BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 76(2):99–125. doi:10.1016/j.pneurobio.2005.06.003
Cavanaugh JE, Ham J, Hetman M, Poser S, Yan C, Xia Z (2001) Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J Neurosci 21(2):434–443
Wang W, Pan YW, Zou J, Li T, Abel GM, Palmiter RD, Storm DR, Xia Z (2014) Genetic activation of ERK5 MAP kinase enhances adult neurogenesis and extends hippocampus-dependent long-term memory. J Neurosci 34(6):2130–2147. doi:10.1523/JNEUROSCI.3324-13.2014
Ohtsuka M, Fukumitsu H, Furukawa S (2009) Neurotrophin-3 stimulates neurogenetic proliferation via the extracellular signal-regulated kinase pathway. J Neurosci Res 87(2):301–306. doi:10.1002/jnr.21855
Aletsee C, Beros A, Mullen L, Palacios S, Pak K, Dazert S, Ryan AF (2001) Ras/MEK but not p38 signaling mediates NT-3-induced neurite extension from spiral ganglion neurons. J Assoc Res Otolaryngol 2(4):377–387
Ming G, Song H, Berninger B, Inagaki N, Tessier-Lavigne M, Poo M (1999) Phospholipase C-gamma and phosphoinositide 3-kinase mediate cytoplasmic signaling in nerve growth cone guidance. Neuron 23(1):139–148
Yamashita T, Higuchi H, Tohyama M (2002) The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho. J Cell Biol 157(4):565–570. doi:10.1083/jcb.200202010
Yamashita T, Tohyama M (2003) The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI. Nat Neurosci 6(5):461–467. doi:10.1038/nn1045
Fujita Y, Yamashita T (2014) Axon growth inhibition by RhoA/ROCK in the central nervous system. Front Neurosci 8:338. doi:10.3389/fnins.2014.00338
Yamada M, Numakawa T, Koshimizu H, Tanabe K, Wada K, Koizumi S, Hatanaka H (2002) Distinct usages of phospholipase C gamma and Shc in intracellular signaling stimulated by neurotrophins. Brain Res 955(1-2):183–190
Numakawa T, Kumamaru E, Adachi N, Yagasaki Y, Izumi A, Kunugi H (2009) Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC-gamma signaling for glutamate release via a glutamate transporter. Proc Natl Acad Sci U S A 106(2):647–652. doi:10.1073/pnas.0800888106
Blanquet PR (2000) Identification of two persistently activated neurotrophin-regulated pathways in rat hippocampus. Neuroscience 95(3):705–719
Blum R, Konnerth A (2005) Neurotrophin-mediated rapid signaling in the central nervous system: mechanisms and functions. Physiology (Bethesda) 20:70–78. doi:10.1152/physiol.00042.2004
Minichiello L, Calella AM, Medina DL, Bonhoeffer T, Klein R, Korte M (2002) Mechanism of TrkB-mediated hippocampal long-term potentiation. Neuron 36(1):121–137
Mizoguchi Y, Ishibashi H, Nabekura J (2003) The action of BDNF on GABA(A) currents changes from potentiating to suppressing during maturation of rat hippocampal CA1 pyramidal neurons. J Physiol 548(Pt 3):703–709. doi:10.1113/jphysiol.2003.038935
Canossa M, Gartner A, Campana G, Inagaki N, Thoenen H (2001) Regulated secretion of neurotrophins by metabotropic glutamate group I (mGluRI) and Trk receptor activation is mediated via phospholipase C signalling pathways. EMBO J 20(7):1640–1650. doi:10.1093/emboj/20.7.1640
Yang F, He X, Feng L, Mizuno K, Liu XW, Russell J, Xiong WC, Lu B (2001) PI-3 kinase and IP3 are both necessary and sufficient to mediate NT3-induced synaptic potentiation. Nat Neurosci 4(1):19–28. doi:10.1038/82858
Lee FS, Chao MV (2001) Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc Natl Acad Sci U S A 98(6):3555–3560. doi:10.1073/pnas.061020198
Lee FS, Rajagopal R, Chao MV (2002) Distinctive features of Trk neurotrophin receptor transactivation by G protein-coupled receptors. Cytokine Growth Factor Rev 13(1):11–17
Domeniconi M, Chao MV (2010) Transactivation of Trk receptors in spinal motor neurons. Histol Histopathol 25(9):1207–1213
Rajagopal R, Chen ZY, Lee FS, Chao MV (2004) Transactivation of Trk neurotrophin receptors by G-protein-coupled receptor ligands occurs on intracellular membranes. J Neurosci 24(30):6650–6658. doi:10.1523/JNEUROSCI.0010-04.2004
Jeanneteau F, Chao MV (2006) Promoting neurotrophic effects by GPCR ligands. Novartis Found Symp 276:181–189, discussion 189–192, 233–187, 275–181
Lee FS, Rajagopal R, Kim AH, Chang PC, Chao MV (2002) Activation of Trk neurotrophin receptor signaling by pituitary adenylate cyclase-activating polypeptides. J Biol Chem 277(11):9096–9102. doi:10.1074/jbc.M107421200
Wiese S, Jablonka S, Holtmann B, Orel N, Rajagopal R, Chao MV, Sendtner M (2007) Adenosine receptor A2A-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. Proc Natl Acad Sci U S A 104(43):17210–17215. doi:10.1073/pnas.0705267104
Puehringer D, Orel N, Luningschror P, Subramanian N, Herrmann T, Chao MV, Sendtner M (2013) EGF transactivation of Trk receptors regulates the migration of newborn cortical neurons. Nat Neurosci 16(4):407–415. doi:10.1038/nn.3333
Fenner BM (2012) Truncated TrkB: beyond a dominant negative receptor. Cytokine Growth Factor Rev 23(1-2):15–24. doi:10.1016/j.cytogfr.2012.01.002
Li YX, Xu Y, Ju D, Lester HA, Davidson N, Schuman EM (1998) Expression of a dominant negative TrkB receptor, T1, reveals a requirement for presynaptic signaling in BDNF-induced synaptic potentiation in cultured hippocampal neurons. Proc Natl Acad Sci U S A 95(18):10884–10889
Steinbeck JA, Methner A (2005) Translational downregulation of the noncatalytic growth factor receptor TrkB.T1 by ischemic preconditioning of primary neurons. Gene Expr 12(2):99–106
Hartmann M, Brigadski T, Erdmann KS, Holtmann B, Sendtner M, Narz F, Lessmann V (2004) Truncated TrkB receptor-induced outgrowth of dendritic filopodia involves the p75 neurotrophin receptor. J Cell Sci 117(Pt 24):5803–5814. doi:10.1242/jcs.01511
Eide FF, Vining ER, Eide BL, Zang K, Wang XY, Reichardt LF (1996) Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci 16(10):3123–3129
Yacoubian TA, Lo DC (2000) Truncated and full-length TrkB receptors regulate distinct modes of dendritic growth. Nat Neurosci 3(4):342–349. doi:10.1038/73911
Brodeur GM, Minturn JE, Ho R et al (2009) Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res 15(10):3244–3250. doi:10.1158/1078-0432.CCR-08-1815
Carim-Todd L, Bath KG, Fulgenzi G et al (2009) Endogenous truncated TrkB.T1 receptor regulates neuronal complexity and TrkB kinase receptor function in vivo. J Neurosci 29(3):678–685. doi:10.1523/JNEUROSCI.5060-08.2009
Ohira K, Funatsu N, Homma KJ, Sahara Y, Hayashi M, Kaneko T, Nakamura S (2007) Truncated TrkB-T1 regulates the morphology of neocortical layer I astrocytes in adult rat brain slices. Eur J Neurosci 25(2):406–416. doi:10.1111/j.1460-9568.2007.05282.x
Ohira K, Kumanogoh H, Sahara Y, Homma KJ, Hirai H, Nakamura S, Hayashi M (2005) A truncated tropomyosin-related kinase B receptor, T1, regulates glial cell morphology via Rho GDP dissociation inhibitor 1. J Neurosci 25(6):1343–1353. doi:10.1523/JNEUROSCI.4436-04.2005
Ohira K, Homma KJ, Hirai H, Nakamura S, Hayashi M (2006) TrkB-T1 regulates the RhoA signaling and actin cytoskeleton in glioma cells. Biochem Biophys Res Commun 342(3):867–874. doi:10.1016/j.bbrc.2006.02.033
Fournier AE, Takizawa BT, Strittmatter SM (2003) Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci 23(4):1416–1423
Kozma R, Sarner S, Ahmed S, Lim L (1997) Rho family GTPases and neuronal growth cone remodelling: relationship between increased complexity induced by Cdc42Hs, Rac1, and acetylcholine and collapse induced by RhoA and lysophosphatidic acid. Mol Cell Biol 17(3):1201–1211
Aroeira RI, Sebastiao AM, Valente CA (2015) BDNF, via truncated TrkB receptor, modulates GlyT1 and GlyT2 in astrocytes. Glia 63(12):2181–2197. doi:10.1002/glia.22884
Michaelsen K, Zagrebelsky M, Berndt-Huch J, Polack M, Buschler A, Sendtner M, Korte M (2010) Neurotrophin receptors TrkB.T1 and p75NTR cooperate in modulating both functional and structural plasticity in mature hippocampal neurons. Eur J Neurosci 32(11):1854–1865. doi:10.1111/j.1460-9568.2010.07460.x
Kryl D, Barker PA (2000) TTIP is a novel protein that interacts with the truncated T1 TrkB neurotrophin receptor. Biochem Biophys Res Commun 279(3):925–930. doi:10.1006/bbrc.2000.4058
Palko ME, Coppola V, Tessarollo L (1999) Evidence for a role of truncated trkC receptor isoforms in mouse development. J Neurosci 19(2):775–782
Menn B, Timsit S, Calothy G, Lamballe F (1998) Differential expression of TrkC catalytic and noncatalytic isoforms suggests that they act independently or in association. J Comp Neurol 401(1):47–64
Esteban PF, Yoon HY, Becker J et al (2006) A kinase-deficient TrkC receptor isoform activates Arf6-Rac1 signaling through the scaffold protein tamalin. J Cell Biol 173(2):291–299. doi:10.1083/jcb.200512013
Ibanez CF, Simi A (2012) p75 neurotrophin receptor signaling in nervous system injury and degeneration: paradox and opportunity. Trends Neurosci 35(7):431–440. doi:10.1016/j.tins.2012.03.007
Hempstead BL, Martin-Zanca D, Kaplan DR, Parada LF, Chao MV (1991) High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature 350(6320):678–683. doi:10.1038/350678a0
Esposito D, Patel P, Stephens RM, Perez P, Chao MV, Kaplan DR, Hempstead BL (2001) The cytoplasmic and transmembrane domains of the p75 and Trk A receptors regulate high affinity binding to nerve growth factor. J Biol Chem 276(35):32687–32695. doi:10.1074/jbc.M011674200
Meeker R, Williams K (2014) Dynamic nature of the p75 neurotrophin receptor in response to injury and disease. J Neuroimmune Pharmacol 9(5):615–628. doi:10.1007/s11481-014-9566-9
Gentry JJ, Rutkoski NJ, Burke TL, Carter BD (2004) A functional interaction between the p75 neurotrophin receptor interacting factors, TRAF6 and NRIF. J Biol Chem 279(16):16646–16656. doi:10.1074/jbc.M309209200
Linggi MS, Burke TL, Williams BB, Harrington A, Kraemer R, Hempstead BL, Yoon SO, Carter BD (2005) Neurotrophin receptor interacting factor (NRIF) is an essential mediator of apoptotic signaling by the p75 neurotrophin receptor. J Biol Chem 280(14):13801–13808. doi:10.1074/jbc.M410435200
Salehi AH, Xanthoudakis S, Barker PA (2002) NRAGE, a p75 neurotrophin receptor-interacting protein, induces caspase activation and cell death through a JNK-dependent mitochondrial pathway. J Biol Chem 277(50):48043–48050. doi:10.1074/jbc.M205324200
Westwick JK, Bielawska AE, Dbaibo G, Hannun YA, Brenner DA (1995) Ceramide activates the stress-activated protein kinases. J Biol Chem 270(39):22689–22692
Brann AB, Tcherpakov M, Williams IM, Futerman AH, Fainzilber M (2002) Nerve growth factor-induced p75-mediated death of cultured hippocampal neurons is age-dependent and transduced through ceramide generated by neutral sphingomyelinase. J Biol Chem 277(12):9812–9818. doi:10.1074/jbc.M109862200
Hamanoue M, Middleton G, Wyatt S, Jaffray E, Hay RT, Davies AM (1999) p75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor. Mol Cell Neurosci 14(1):28–40. doi:10.1006/mcne.1999.0770
Khursigara G, Orlinick JR, Chao MV (1999) Association of the p75 neurotrophin receptor with TRAF6. J Biol Chem 274(5):2597–2600
Carter BD, Kaltschmidt C, Kaltschmidt B, Offenhauser N, Bohm-Matthaei R, Baeuerle PA, Barde YA (1996) Selective activation of NF-kappa B by nerve growth factor through the neurotrophin receptor p75. Science 272(5261):542–545
Khursigara G, Bertin J, Yano H, Moffett H, DiStefano PS, Chao MV (2001) A prosurvival function for the p75 receptor death domain mediated via the caspase recruitment domain receptor-interacting protein 2. J Neurosci 21(16):5854–5863
Lebrun-Julien F, Bertrand MJ, De Backer O, Stellwagen D, Morales CR, Di Polo A, Barker PA (2010) ProNGF induces TNFalpha-dependent death of retinal ganglion cells through a p75NTR non-cell-autonomous signaling pathway. Proc Natl Acad Sci U S A 107(8):3817–3822. doi:10.1073/pnas.0909276107
Volosin M, Trotter C, Cragnolini A, Kenchappa RS, Light M, Hempstead BL, Carter BD, Friedman WJ (2008) Induction of proneurotrophins and activation of p75NTR-mediated apoptosis via neurotrophin receptor-interacting factor in hippocampal neurons after seizures. J Neurosci 28(39):9870–9879. doi:10.1523/JNEUROSCI.2841-08.2008
Kenchappa RS, Zampieri N, Chao MV, Barker PA, Teng HK, Hempstead BL, Carter BD (2006) Ligand-dependent cleavage of the P75 neurotrophin receptor is necessary for NRIF nuclear translocation and apoptosis in sympathetic neurons. Neuron 50(2):219–232. doi:10.1016/j.neuron.2006.03.011
Geetha T, Kenchappa RS, Wooten MW, Carter BD (2005) TRAF6-mediated ubiquitination regulates nuclear translocation of NRIF, the p75 receptor interactor. EMBO J 24(22):3859–3868. doi:10.1038/sj.emboj.7600845
Chen J, Wu X, Shao B, Zhao W, Shi W, Zhang S, Ni L, Shen A (2011) Increased expression of TNF receptor-associated factor 6 after rat traumatic brain injury. Cell Mol Neurobiol 31(2):269–275. doi:10.1007/s10571-010-9617-6
Wu X, Xu XM (2016) RhoA/Rho kinase in spinal cord injury. Neural Regen Res 11(1):23–27. doi:10.4103/1673-5374.169601
Meeker RB, Williams KS (2015) The p75 neurotrophin receptor: at the crossroad of neural repair and death. Neural Regen Res 10(5):721–725. doi:10.4103/1673-5374.156967
Yamashita T, Tucker KL, Barde YA (1999) Neurotrophin binding to the p75 receptor modulates Rho activity and axonal outgrowth. Neuron 24(3):585–593. doi:10.1016/S0896-6273(00)81114-9
Song W, Volosin M, Cragnolini AB, Hempstead BL, Friedman WJ (2010) ProNGF induces PTEN via p75NTR to suppress Trk-mediated survival signaling in brain neurons. J Neurosci 30(46):15608–15615. doi:10.1523/JNEUROSCI.2581-10.2010
Sheng M, Sabatini BL, Sudhof TC (2012) Synapses and Alzheimer’s disease. Cold Spring Harb Perspect Biol 4(5). doi:10.1101/cshperspect.a005777
Picconi B, Piccoli G, Calabresi P (2012) Synaptic dysfunction in Parkinson’s disease. Adv Exp Med Biol 970:553–572. doi:10.1007/978-3-7091-0932-8_24
Sudhof TC, Rizo J (2011) Synaptic vesicle exocytosis. Cold Spring Harb Perspect Biol 3(12). doi:10.1101/cshperspect.a005637
Calabresi P, Mercuri NB, Di Filippo M (2009) Synaptic plasticity, dopamine and Parkinson’s disease: one step ahead. Brain 132(Pt 2):285–287. doi:10.1093/brain/awn340
Tancredi V, D’Arcangelo G, Mercanti D, Calissano P (1993) Nerve growth factor inhibits the expression of long-term potentiation in hippocampal slices. Neuroreport 4(2):147–150
Brancucci A, Kuczewski N, Covaceuszach S, Cattaneo A, Domenici L (2004) Nerve growth factor favours long-term depression over long-term potentiation in layer II-III neurones of rat visual cortex. J Physiol 559(Pt 2):497–506. doi:10.1113/jphysiol.2004.068049
Akaneya Y, Tsumoto T, Kinoshita S, Hatanaka H (1997) Brain-derived neurotrophic factor enhances long-term potentiation in rat visual cortex. J Neurosci 17(17):6707–6716
Conner JM, Franks KM, Titterness AK, Russell K, Merrill DA, Christie BR, Sejnowski TJ, Tuszynski MH (2009) NGF is essential for hippocampal plasticity and learning. J Neurosci 29(35):10883–10889. doi:10.1523/JNEUROSCI.2594-09.2009
Arias ER, Valle-Leija P, Morales MA, Cifuentes F (2014) Differential contribution of BDNF and NGF to long-term potentiation in the superior cervical ganglion of the rat. Neuropharmacology 81:206–214. doi:10.1016/j.neuropharm.2014.02.001
Edelmann E, Lessmann V, Brigadski T (2014) Pre- and postsynaptic twists in BDNF secretion and action in synaptic plasticity. Neuropharmacology 76(Pt C):610–627. doi:10.1016/j.neuropharm.2013.05.043
Lu B, Nagappan G, Lu Y (2014) BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb Exp Pharmacol 220:223–250. doi:10.1007/978-3-642-45106-5_9
Patterson SL, Grover LM, Schwartzkroin PA, Bothwell M (1992) Neurotrophin expression in rat hippocampal slices: a stimulus paradigm inducing LTP in CA1 evokes increases in BDNF and NT-3 mRNAs. Neuron 9(6):1081–1088
Figurov A, Pozzo-Miller LD, Olafsson P, Wang T, Lu B (1996) Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 381(6584):706–709. doi:10.1038/381706a0
Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T (1995) Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci U S A 92(19):8856–8860
Patterson SL, Abel T, Deuel TA, Martin KC, Rose JC, Kandel ER (1996) Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. Neuron 16(6):1137–1145
Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, Hempstead BL, Lu B (2005) Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci 8(8):1069–1077. doi:10.1038/nn1510
Matsumoto T, Rauskolb S, Polack M, Klose J, Kolbeck R, Korte M, Barde YA (2008) Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat Neurosci 11(2):131–133. doi:10.1038/nn2038
Bliss TV, Cooke SF (2011) Long-term potentiation and long-term depression: a clinical perspective. Clinics (Sao Paulo) 66(Suppl 1):3–17
Bliss TV, Collingridge GL, Morris RG (2014) Synaptic plasticity in health and disease: introduction and overview. Philos Trans R Soc Lond B Biol Sci 369 (1633):20130129. doi:10.1098/rstb.2013.0129
Chen G, Kolbeck R, Barde YA, Bonhoeffer T, Kossel A (1999) Relative contribution of endogenous neurotrophins in hippocampal long-term potentiation. J Neurosci 19(18):7983–7990
Ma L, Reis G, Parada LF, Schuman EM (1999) Neuronal NT-3 is not required for synaptic transmission or long-term potentiation in area CA1 of the adult rat hippocampus. Learn Mem 6(3):267–275
Kaplan DR, Cooper E (2001) PI-3 kinase and IP3: partners in NT3-induced synaptic transmission. Nat Neurosci 4(1):5–7. doi:10.1038/82897
Galvan EJ, Cosgrove KE, Barrionuevo G (2011) Multiple forms of long-term synaptic plasticity at hippocampal mossy fiber synapses on interneurons. Neuropharmacology 60(5):740–747. doi:10.1016/j.neuropharm.2010.11.008
Ramos-Languren LE, Escobar ML (2013) Plasticity and metaplasticity of adult rat hippocampal mossy fibers induced by neurotrophin-3. Eur J Neurosci 37(8):1248–1259. doi:10.1111/ejn.12141
Xie CW, Sayah D, Chen QS, Wei WZ, Smith D, Liu X (2000) Deficient long-term memory and long-lasting long-term potentiation in mice with a targeted deletion of neurotrophin-4 gene. Proc Natl Acad Sci U S A 97(14):8116–8121. doi:10.1073/pnas.140204597
Fan G, Egles C, Sun Y, Minichiello L, Renger JJ, Klein R, Liu G, Jaenisch R (2000) Knocking the NT4 gene into the BDNF locus rescues BDNF deficient mice and reveals distinct NT4 and BDNF activities. Nat Neurosci 3(4):350–357. doi:10.1038/73921
Zeng Y, Zhao D, Xie CW (2010) Neurotrophins enhance CaMKII activity and rescue amyloid-beta-induced deficits in hippocampal synaptic plasticity. J Alzheimers Dis 21(3):823–831. doi:10.3233/JAD-2010-100264
Callaghan CK, Kelly AM (2013) Neurotrophins play differential roles in short and long-term recognition memory. Neurobiol Learn Mem 104:39–48. doi:10.1016/j.nlm.2013.04.011
Wondolowski J, Dickman D (2013) Emerging links between homeostatic synaptic plasticity and neurological disease. Front Cell Neurosci 7:223. doi:10.3389/fncel.2013.00223
Stewart MH, Bendall SC, Bhatia M (2008) Deconstructing human embryonic stem cell cultures: niche regulation of self-renewal and pluripotency. J Mol Med (Berl) 86(8):875–886. doi:10.1007/s00109-008-0356-9
Amit M, Carpenter MK, Inokuma MS, Chiu CP, Harris CP, Waknitz MA, Itskovitz-Eldor J, Thomson JA (2000) Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol 227(2):271–278. doi:10.1006/dbio.2000.9912
Schuldiner M, Yanuka O, Itskovitz-Eldor J, Melton DA, Benvenisty N (2000) Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 97(21):11307–11312. doi:10.1073/pnas.97.21.11307
Bentz K, Molcanyi M, Riess P et al (2007) Embryonic stem cells produce neurotrophins in response to cerebral tissue extract: Cell line-dependent differences. J Neurosci Res 85(5):1057–1064. doi:10.1002/jnr.21219
Moscatelli I, Pierantozzi E, Camaioni A, Siracusa G, Campagnolo L (2009) p75 neurotrophin receptor is involved in proliferation of undifferentiated mouse embryonic stem cells. Exp Cell Res 315(18):3220–3232. doi:10.1016/j.yexcr.2009.08.014
Wobus AM, Grosse R, Schoneich J (1988) Specific effects of nerve growth factor on the differentiation pattern of mouse embryonic stem cells in vitro. Biomed Biochim Acta 47(12):965–973
Schuldiner M, Eiges R, Eden A, Yanuka O, Itskovitz-Eldor J, Goldstein RS, Benvenisty N (2001) Induced neuronal differentiation of human embryonic stem cells. Brain Res 913(2):201–205. doi:10.1016/S0006-8993(01)02776-7
Levenberg S, Burdick JA, Kraehenbuehl T, Langer R (2005) Neurotrophin-induced differentiation of human embryonic stem cells on three-dimensional polymeric scaffolds. Tissue Eng 11(3-4):506–512. doi:10.1089/ten.2005.11.506
Leschik J, Eckenstaler R, Nieweg K, Lichtenecker P, Brigadski T, Gottmann K, Lessmann V, Lutz B (2013) Embryonic stem cells stably expressing BDNF-GFP exhibit a BDNF-release-dependent enhancement of neuronal differentiation. J Cell Sci 126(Pt 21):5062–5073. doi:10.1242/jcs.135384
Xu R, Srinivasan SP, Sureshkumar P et al (2015) Effects of synthetic neural adhesion molecule mimetic peptides and related proteins on the cardiomyogenic differentiation of mouse embryonic stem cells. Cell Physiol Biochem 35(6):2437–2450. doi:10.1159/000374044
Gage FH, Temple S (2013) Neural stem cells: generating and regenerating the brain. Neuron 80(3):588–601. doi:10.1016/j.neuron.2013.10.037
Lindvall O, Kokaia Z (2011) Stem cell research in stroke: how far from the clinic? Stroke 42(8):2369–2375. doi:10.1161/STROKEAHA.110.599654
Tong LM, Fong H, Huang Y (2015) Stem cell therapy for Alzheimer’s disease and related disorders: current status and future perspectives. Exp Mol Med 47, e151. doi:10.1038/emm.2014.124
Islam O, Loo TX, Heese K (2009) Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways. Curr Neurovasc Res 6(1):42–53. doi:10.2174/156720209787466028#sthash.4DDR9O4h.dpuf
Lachyankar MB, Condon PJ, Quesenberry PJ, Litofsky NS, Recht LD, Ross AH (1997) Embryonic precursor cells that express Trk receptors: induction of different cell fates by NGF, BDNF, NT-3, and CNTF. Exp Neurol 144(2):350–360. doi:10.1006/exnr.1997.6434
Ahmed S, Reynolds B, Weiss S (1995) BDNF enhances the differentiation but not the survival of CNS stem cell- derived neuronal precursors. J Neurosci 15(8):5765–5778
Yan Q, Radeke MJ, Matheson CR, Talvenheimo J, Welcher AA, Feinstein SC (1997) Immunocytochemical localization of TrkB in the central nervous system of the adult rat. J Comp Neurol 378(1):135–157. doi:10.1002/(SICI)1096-9861(19970203)378:1<135::AID-CNE8>3.0.CO;2-5
Fong SP, Tsang KS, Chan AB, Lu G, Poon WS, Li K, Baum LW, Ng HK (2007) Trophism of neural progenitor cells to embryonic stem cells: neural induction and transplantation in a mouse ischemic stroke model. J Neurosci Res 85(9):1851–1862. doi:10.1002/jnr.21319
Takahashi J, Palmer TD, Gage FH (1999) Retinoic acid and neurotrophins collaborate to regulate neurogenesis in adult-derived neural stem cell cultures. J Neurobiol 38(1):65–81. doi:10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.0.CO;2-Q
Barnabe-Heider F, Miller FD (2003) Endogenously produced neurotrophins regulate survival and differentiation of cortical progenitors via distinct signaling pathways. J Neurosci 23(12):5149–5160
Temple S, Qian X (1995) bFGF, neurotrophins, and the control or cortical neurogenesis. Neuron 15(2):249–252. doi:10.1016/0896-6273(95)90030-6
Caldwell MA, He X, Wilkie N, Pollack S, Marshall G, Wafford KA, Svendsen CN (2001) Growth factors regulate the survival and fate of cells derived from human neurospheres. Nat Biotechnol 19(5):475–479. doi:10.1038/88158
Liu F, Xuan A, Chen Y, Zhang J, Xu L, Yan Q, Long D (2014) Combined effect of nerve growth factor and brainderived neurotrophic factor on neuronal differentiation of neural stem cells and the potential molecular mechanisms. Mol Med Rep 10(4):1739–1745. doi:10.3892/mmr.2014.2393
Ito H, Nakajima A, Nomoto H, Furukawa S (2003) Neurotrophins facilitate neuronal differentiation of cultured neural stem cells via induction of mRNA expression of basic helix-loop-helix transcription factors Mash1 and Math1. J Neurosci Res 71(5):648–658. doi:10.1002/jnr.10532
Chen BY, Wang X, Wang ZY, Wang YZ, Chen LW, Luo ZJ (2013) Brain-derived neurotrophic factor stimulates proliferation and differentiation of neural stem cells, possibly by triggering the Wnt/beta-catenin signaling pathway. J Neurosci Res 91(1):30–41. doi:10.1002/jnr.23138
Tervonen TA, Ajamian F, De Wit J, Verhaagen J, Castren E, Castren M (2006) Overexpression of a truncated TrkB isoform increases the proliferation of neural progenitors. Eur J Neurosci 24(5):1277–1285. doi:10.1111/j.1460-9568.2006.05010.x
Chen SQ, Cai Q, Shen YY, Cai XY, Lei HY (2014) Combined use of NGF/BDNF/bFGF promotes proliferation and differentiation of neural stem cells in vitro. Int J Dev Neurosci 38:74–78. doi:10.1016/j.ijdevneu.2014.08.002
Lu HX, Hao ZM, Jiao Q et al (2011) Neurotrophin-3 gene transduction of mouse neural stem cells promotes proliferation and neuronal differentiation in organotypic hippocampal slice cultures. Med Sci Monit 17(11):BR305–BR311. doi:10.12659/MSM.882039
Jin L, Hu X, Feng L (2005) NT3 inhibits FGF2-induced neural progenitor cell proliferation via the PI3K/GSK3 pathway. J Neurochem 93(5):1251–1261. doi:10.1111/j.1471-4159.2005.03118.x
Jansson LC, Louhivuori L, Wigren HK, Nordstrom T, Louhivuori V, Castren ML, Akerman KE (2012) Brain-derived neurotrophic factor increases the motility of a particular N-methyl-D-aspartate/GABA-responsive subset of neural progenitor cells. Neuroscience 224:223–234. doi:10.1016/j.neuroscience.2012.08.038
Grade S, Weng YC, Snapyan M, Kriz J, Malva JO, Saghatelyan A (2013) Brain-derived neurotrophic factor promotes vasculature-associated migration of neuronal precursors toward the ischemic striatum. PLoS One 8(1), e55039. doi:10.1371/journal.pone.0055039
Zhang Q, Liu G, Wu Y, Sha H, Zhang P, Jia J (2011) BDNF promotes EGF-induced proliferation and migration of human fetal neural stem/progenitor cells via the PI3K/Akt pathway. Molecules 16(12):10146–10156. doi:10.3390/molecules161210146
Behar TN, Dugich-Djordjevic MM, Li YX et al (1997) Neurotrophins stimulate chemotaxis of embryonic cortical neurons. Eur J Neurosci 9(12):2561–2570. doi:10.1111/j.1460-9568.1997.tb01685.x
Delgado AC, Ferron SR, Vicente D, Porlan E, Perez-Villalba A, Trujillo CM, D’Ocon P, Farinas I (2014) Endothelial NT-3 delivered by vasculature and CSF promotes quiescence of subependymal neural stem cells through nitric oxide induction. Neuron 83(3):572–585. doi:10.1016/j.neuron.2014.06.015
Lindvall O, Ernfors P, Bengzon J, Kokaia Z, Smith ML, Siesjo BK, Persson H (1992) Differential regulation of mRNAs for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the adult rat brain following cerebral ischemia and hypoglycemic coma. Proc Natl Acad Sci U S A 89(2):648–652
Kokaia Z, Andsberg G, Yan Q, Lindvall O (1998) Rapid alterations of BDNF protein levels in the rat brain after focal ischemia: evidence for increased synthesis and anterograde axonal transport. Exp Neurol 154(2):289–301. doi:10.1006/exnr.1998.6888
Kokaia Z, Zhao Q, Kokaia M, Elmer E, Metsis M, Smith ML, Siesjo BK, Lindvall O (1995) Regulation of brain-derived neurotrophic factor gene expression after transient middle cerebral artery occlusion with and without brain damage. Exp Neurol 136(1):73–88. doi:10.1006/exnr.1995.1085
Sulejczak D, Ziemlinska E, Czarkowska-Bauch J, Nosecka E, Strzalkowski R, Skup M (2007) Focal photothrombotic lesion of the rat motor cortex increases BDNF levels in motor-sensory cortical areas not accompanied by recovery of forelimb motor skills. J Neurotrauma 24(8):1362–1377. doi:10.1089/neu.2006.0261
Bejot Y, Prigent-Tessier A, Cachia C, Giroud M, Mossiat C, Bertrand N, Garnier P, Marie C (2011) Time-dependent contribution of non neuronal cells to BDNF production after ischemic stroke in rats. Neurochem Int 58(1):102–111. doi:10.1016/j.neuint.2010.10.019
Park KI, Hack MA, Ourednik J et al (2006) Acute injury directs the migration, proliferation, and differentiation of solid organ stem cells: evidence from the effect of hypoxia-ischemia in the CNS on clonal “reporter” neural stem cells. Exp Neurol 199(1):156–178. doi:10.1016/j.expneurol.2006.04.002
Park KI, Teng YD, Snyder EY (2002) The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue. Nat Biotechnol 20(11):1111–1117. doi:10.1038/nbt751
Imitola J, Raddassi K, Park KI et al (2004) Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A 101(52):18117–18122. doi:10.1073/pnas.0408258102
Aboody KS, Brown A, Rainov NG et al (2000) Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A 97(23):12846–12851. doi:10.1073/pnas.97.23.12846
Kelly S, Bliss TM, Shah AK et al (2004) Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci U S A 101(32):11839–11844. doi:10.1073/pnas.0404474101
Shear DA, Tate MC, Archer DR, Hoffman SW, Hulce VD, Laplaca MC, Stein DG (2004) Neural progenitor cell transplants promote long-term functional recovery after traumatic brain injury. Brain Res 1026(1):11–22. doi:10.1016/j.brainres.2004.07.087
Flax JD, Aurora S, Yang C et al (1998) Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes. Nat Biotechnol 16(11):1033–1039. doi:10.1038/3473
Snapyan M, Lemasson M, Brill MS et al (2009) Vasculature guides migrating neuronal precursors in the adult mammalian forebrain via brain-derived neurotrophic factor signaling. J Neurosci 29(13):4172–4188. doi:10.1523/JNEUROSCI.4956-08.2009
Caplan AI (1991) Mesenchymal stem cells. J Orthop Res 9(5):641–650. doi:10.1002/jor.1100090504
Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views. Stem Cells 25(11):2896–2902. doi:10.1634/stemcells.2007-0637
Fan X, Sun D, Tang X, Cai Y, Yin ZQ, Xu H (2014) Stem-cell challenges in the treatment of Alzheimer’s disease: a long way from bench to bedside. Med Res Rev 34(5):957–978. doi:10.1002/med.21309
Williams AR, Hare JM (2011) Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 109(8):923–940. doi:10.1161/CIRCRESAHA.111.243147
Bianco P, Riminucci M, Gronthos S, Robey PG (2001) Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19(3):180–192. doi:10.1634/stemcells.19-3-180
Frenette PS, Pinho S, Lucas D, Scheiermann C (2013) Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu Rev Immunol 31(1):285–316. doi:10.1146/annurev-immunol-032712-095919
Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA (2010) Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med 5(6):933–946. doi:10.2217/rme.10.72
Wyse RD, Dunbar GL, Rossignol J (2014) Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases. Int J Mol Sci 15(2):1719–1745. doi:10.3390/ijms15021719
Yaghoobi MM, Mowla SJ (2006) Differential gene expression pattern of neurotrophins and their receptors during neuronal differentiation of rat bone marrow stromal cells. Neurosci Lett 397(1-2):149–154. doi:10.1016/j.neulet.2005.12.009
Ribeiro CA, Salgado AJ, Fraga JS, Silva NA, Reis RL, Sousa N (2011) The secretome of bone marrow mesenchymal stem cells-conditioned media varies with time and drives a distinct effect on mature neurons and glial cells (primary cultures). J Tissue Eng Regen Med 5(8):668–672. doi:10.1002/term.365
Greenberg ME, Xu B, Lu B, Hempstead BL (2009) New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci 29(41):12764–12767. doi:10.1523/JNEUROSCI.3566-09.2009
Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG (2006) Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol 198(1):54–64. doi:10.1016/j.expneurol.2005.10.029
Montzka K, Fuhrmann T, Muller-Ehmsen J, Woltje M, Brook GA (2010) Growth factor and cytokine expression of human mesenchymal stromal cells is not altered in an in vitro model of tissue damage. Cytotherapy 12(7):870–880. doi:10.3109/14653249.2010.501789
Woodbury D, Schwarz EJ, Prockop DJ, Black IB (2000) Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 61(4):364–370
Munoz-Elias G, Marcus AJ, Coyne TM, Woodbury D, Black IB (2004) Adult bone marrow stromal cells in the embryonic brain: engraftment, migration, differentiation, and long-term survival. J Neurosci 24(19):4585–4595. doi:10.1523/JNEUROSCI.5060-03.2004
Sanchez-Ramos J, Song S, Cardozo-Pelaez F et al (2000) Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol 164(2):247–256. doi:10.1006/exnr.2000.7389
Mezey E, Key S, Vogelsang G, Szalayova I, Lange GD, Crain B (2003) Transplanted bone marrow generates new neurons in human brains. Proc Natl Acad Sci U S A 100(3):1364–1369. doi:10.1073/pnas.0336479100
Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC (2002) Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol 174(1):11–20. doi:10.1006/exnr.2001.7853
Segal-Gavish H, Karvat G, Barak N et al (2016) Mesenchymal stem cell transplantation promotes neurogenesis and ameliorates autism related behaviors in BTBR mice. Autism Res 9(1):17–32. doi:10.1002/aur.1530
Hsieh JY, Wang HW, Chang SJ et al (2013) Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS One 8(8), e72604. doi:10.1371/journal.pone.0072604
Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, Scolding N (2009) Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res 3(1):63–70. doi:10.1016/j.scr.2009.02.006
Asahara T, Masuda H, Takahashi T et al (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85(3):221–228
Blais M, Levesque P, Bellenfant S, Berthod F (2013) Nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and glial-derived neurotrophic factor enhance angiogenesis in a tissue-engineered in vitro model. Tissue Eng A 19(15-16):1655–1664. doi:10.1089/ten.tea.2012.0745
Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, Werner C (2004) Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22(3):377–384. doi:10.1634/stemcells.22-3-377
Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, Thiele CJ (2006) Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Res 66(8):4249–4255. doi:10.1158/0008-5472.CAN-05-2789
Li Q, Ford MC, Lavik EB, Madri JA (2006) Modeling the neurovascular niche: VEGF- and BDNF-mediated cross-talk between neural stem cells and endothelial cells: an in vitro study. J Neurosci Res 84(8):1656–1668. doi:10.1002/jnr.21087
Shen L, Zeng W, Wu YX et al (2013) Neurotrophin-3 accelerates wound healing in diabetic mice by promoting a paracrine response in mesenchymal stem cells. Cell Transplant 22(6):1011–1021. doi:10.3727/096368912X657495
Akiyama Y, Mikami Y, Watanabe E et al (2014) The P75 neurotrophin receptor regulates proliferation of the human MG63 osteoblast cell line. Differentiation 87(3-4):111–118. doi:10.1016/j.diff.2014.01.002
Mikami Y, Suzuki S, Ishii Y, Watanabe N, Takahashi T, Isokawa K, Honda MJ (2012) The p75 neurotrophin receptor regulates MC3T3-E1 osteoblastic differentiation. Differentiation 84(5):392–399. doi:10.1016/j.diff.2012.07.001
Mogi M, Kondo A, Kinpara K, Togari A (2000) Anti-apoptotic action of nerve growth factor in mouse osteoblastic cell line. Life Sci 67(10):1197–1206. doi:10.1016/S0024-3205(00)00705-0
Seita J, Weissman IL (2010) Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med 2(6):640–653. doi:10.1002/wsbm.86
Morrison SJ, Scadden DT (2014) The bone marrow niche for haematopoietic stem cells. Nature 505(7483):327–334. doi:10.1038/nature12984
Traycoff CM, Abboud MR, Laver J, Clapp DW, Hoffman R, Law P, Srour EF (1994) Human umbilical cord blood hematopoietic progenitor cells: are they the same as their adult bone marrow counterparts? Blood Cells 20(2-3):382–390, discussion 390-381
Chevalier S, Praloran V, Smith C et al (1994) Expression and functionality of the trkA proto-oncogene product/NGF receptor in undifferentiated hematopoietic cells. Blood 83(6):1479–1485
Cattoretti G, Schiro R, Orazi A, Soligo D, Colombo MP (1993) Bone marrow stroma in humans: anti-nerve growth factor receptor antibodies selectively stain reticular cells in vivo and in vitro. Blood 81(7):1726–1738
Simone MD, De Santis S, Vigneti E, Papa G, Amadori S, Aloe L (1999) Nerve growth factor: a survey of activity on immune and hematopoietic cells. Hematol Oncol 17(1):1–10
Bracci-Laudiero L, Celestino D, Starace G et al (2003) CD34-positive cells in human umbilical cord blood express nerve growth factor and its specific receptor TrkA. J Neuroimmunol 136(1-2):130–139. doi:10.1016/S0165-5728(03)00007-9
Matsuda H, Coughlin MD, Bienenstock J, Denburg JA (1988) Nerve growth factor promotes human hemopoietic colony growth and differentiation. Proc Natl Acad Sci U S A 85(17):6508–6512
Kannan Y, Matsuda H, Ushio H, Kawamoto K, Shimada Y (1993) Murine granulocyte-macrophage and mast cell colony formation promoted by nerve growth factor. Int Arch Allergy Immunol 102(4):362–367
Matsuda H, Kannan Y, Ushio H, Kiso Y, Kanemoto T, Suzuki H, Kitamura Y (1991) Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow cells. J Exp Med 174(1):7–14. doi:10.1084/jem.174.1.7
Tsuda T, Wong D, Dolovich J, Bienenstock J, Marshall J, Denburg JA (1991) Synergistic effects of nerve growth factor and granulocyte-macrophage colony-stimulating factor on human basophilic cell differentiation. Blood 77(5):971–979
Hamada A, Watanabe N, Ohtomo H, Matsuda H (1996) Nerve growth factor enhances survival and cytotoxic activity of human eosinophils. Br J Haematol 93(2):299–302
Noga O, Englmann C, Hanf G, Grutzkau A, Guhl S, Kunkel G (2002) Activation of the specific neurotrophin receptors TrkA, TrkB and TrkC influences the function of eosinophils. Clin Exp Allergy 32(9):1348–1354
Hahn C, Islamian AP, Renz H, Nockher WA (2006) Airway epithelial cells produce neurotrophins and promote the survival of eosinophils during allergic airway inflammation. J Allergy Clin Immunol 117(4):787–794. doi:10.1016/j.jaci.2005.12.1339
Noga O, Englmann C, Hanf G, Grutzkau A, Seybold J, Kunkel G (2003) The production, storage and release of the neurotrophins nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 by human peripheral eosinophils in allergics and non-allergics. Clin Exp Allergy 33(5):649–654
Nassenstein C, Braun A, Erpenbeck VJ et al (2003) The neurotrophins nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 are survival and activation factors for eosinophils in patients with allergic bronchial asthma. J Exp Med 198(3):455–467. doi:10.1084/jem.20010897
Bischoff SC, Dahinden CA (1992) Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils. Blood 79(10):2662–2669
Bürgi B, Otten UH, Ochensberger B, Rihs S, Heese K, Ehrhard PB, Ibanez CF, Dahinden CA (1996) Basophil priming by neurotrophic factors. Activation through the trk receptor. J Immunol 157(12):5582–5588
Wohrer S, Knapp DJ, Copley MR et al (2014) Distinct stromal cell factor combinations can separately control hematopoietic stem cell survival, proliferation, and self-renewal. Cell Rep 7(6):1956–1967. doi:10.1016/j.celrep.2014.05.014
Besser M, Wank R (1999) Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and Neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 162(11):6303–6306
Schuhmann B, Dietrich A, Sel S et al (2005) A role for brain-derived neurotrophic factor in B cell development. J Neuroimmunol 163(1–2):15–23. doi:10.1016/j.jneuroim.2005.01.023
Li Z, Beutel G, Rhein M et al (2009) High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood 113(9):2028–2037. doi:10.1182/blood-2008-05-155200
Yang M, Huang K, Busche G, Ganser A, Li Z (2014) Activation of TRKB receptor in murine hematopoietic stem/progenitor cells induced mastocytosis. Blood 124(7):1196–1197. doi:10.1182/blood-2014-03-560466
Celebi B, Mantovani D, Pineault N (2012) Insulin-like growth factor binding protein-2 and neurotrophin 3 synergize together to promote the expansion of hematopoietic cells ex vivo. Cytokine 58(3):327–331. doi:10.1016/j.cyto.2012.02.011
DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 27(5):457–464. doi:10.1002/ana.410270502
Scheff SW, DeKosky ST, Price DA (1990) Quantitative assessment of cortical synaptic density in Alzheimer’s disease. Neurobiol Aging 11(1):29–37. doi:10.1016/0197-4580(90)90059-9
Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging 27(10):1372–1384. doi:10.1016/j.neurobiolaging.2005.09.012
Scheff SW, Price DA (1993) Synapse loss in the temporal lobe in Alzheimer’s disease. Ann Neurol 33(2):190–199. doi:10.1002/ana.410330209
Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16(3):285–298. doi:10.1016/0197-4580(95)00013-5, discussion 298-304
Lue LF, Kuo YM, Roher AE et al (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155(3):853–862. doi:10.1016/S0002-9440(10)65184-X
Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid beta-peptide. Trends Mol Med 7(12):548–554. doi:10.1016/S1471-4914(01)02173-6
LaFerla FM (2002) Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease. Nat Rev Neurosci 3(11):862–872. doi:10.1038/nrn960
Bezprozvanny I, Mattson MP (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci 31(9):454–463. doi:10.1016/j.tins.2008.06.005
Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113):787–795. doi:10.1038/nature05292
Shankar GM, Li S, Mehta TH et al (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14(8):837–842. doi:10.1038/nm1782
Almeida CG, Takahashi RH, Gouras GK (2006) Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci 26(16):4277–4288. doi:10.1523/JNEUROSCI.5078-05.2006
Gregori L, Fuchs C, Figueiredo-Pereira ME, Van Nostrand WE, Goldgaber D (1995) Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J Biol Chem 270(34):19702–19708
Sulistio YA, Heese K (2016) The ubiquitin-proteasome system and molecular chaperone deregulation in Alzheimer’s disease. Mol Neurobiol 53(2):905–931. doi:10.1007/s12035-014-9063-4
Walker LC, Jucker M (2015) Neurodegenerative diseases: expanding the prion concept. Annu Rev Neurosci 38(1):87–103. doi:10.1146/annurev-neuro-071714-033828
De Vos KJ, Grierson AJ, Ackerley S, Miller CC (2008) Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 31(1):151–173. doi:10.1146/annurev.neuro.31.061307.090711
Spillantini MG, Goedert M (2013) Tau pathology and neurodegeneration. Lancet Neurol 12(6):609–622. doi:10.1016/S1474-4422(13)70090-5
Stokin GB, Lillo C, Falzone TL et al (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science 307(5713):1282–1288. doi:10.1126/science.1105681
Frost B, Diamond MI (2010) Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11(3):155–159. doi:10.1038/nrn2786
Goedert M (2015) Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science 349(6248):1255555. doi:10.1126/science.1255555
Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer’s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68(3):209–245. doi:10.1016/S0301-0082(02)00079-5
Coyle JT, Price DL, DeLong MR (1983) Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219(4589):1184–1190. doi:10.1126/science.6338589
Gutierrez H, Miranda MI, Bermudez-Rattoni F (1997) Learning impairment and cholinergic deafferentation after cortical nerve growth factor deprivation. J Neurosci 17(10):3796–3803
Prakash N, Cohen-Cory S, Penschuck S, Frostig RD (2004) Basal forebrain cholinergic system is involved in rapid nerve growth factor (NGF)-induced plasticity in the barrel cortex of adult rats. J Neurophysiol 91(1):424–437. doi:10.1152/jn.00489.2003
Backman C, Rose GM, Hoffer BJ, Henry MA, Bartus RT, Friden P, Granholm AC (1996) Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy. J Neurosci 16(17):5437–5442
Hefti F (1986) Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 6(8):2155–2162
Hatanaka H, Tsukui H, Nihonmatsu I (1988) Developmental change in the nerve growth factor action from induction of choline acetyltransferase to promotion of cell survival in cultured basal forebrain cholinergic neurons from postnatal rats. Brain Res 467(1):85–95. doi:10.1016/0165-3806(88)90069-7
Williams LR, Varon S, Peterson GM, Wictorin K, Fischer W, Bjorklund A, Gage FH (1986) Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci U S A 83(23):9231–9235
Mobley WC, Rutkowski JL, Tennekoon GI, Gemski J, Buchanan K, Johnston MV (1986) Nerve growth factor increases choline acetyltransferase activity in developing basal forebrain neurons. Brain Res 387(1):53–62. doi:10.1016/0169-328X(86)90020-3
Alderson RF, Alterman AL, Barde YA, Lindsay RM (1990) Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron 5(3):297–306. doi:10.1016/0896-6273(90)90166-D
Ghosh A, Carnahan J, Greenberg ME (1994) Requirement for BDNF in activity-dependent survival of cortical neurons. Science 263(5153):1618–1623. doi:10.1126/science.7907431
Lindholm D, Carroll P, Tzimagiogis G, Thoenen H (1996) Autocrine-paracrine regulation of hippocampal neuron survival by IGF-1 and the neurotrophins BDNF, NT-3 and NT-4. Eur J Neurosci 8(7):1452–1460
Hock C, Heese K, Hulette C, Rosenberg C, Otten U (2000) Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 57(6):846–851. doi:10.1001/archneur.57.6.846
Forlenza OV, Miranda AS, Guimar I, Talib LL, Diniz BS, Gattaz WF, Teixeira AL (2015) Decreased neurotrophic support is associated with cognitive decline in non-demented subjects. J Alzheimers Dis 46(2):423–429. doi:10.3233/JAD-150172
Crutcher KA, Scott SA, Liang S, Everson WV, Weingartner J (1993) Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer’s disease. J Neurosci 13(6):2540–2550
Hellweg R, Gericke CA, Jendroska K, Hartung HD, Cervos-Navarro J (1998) NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer’s disease. Int J Dev Neurosci 16(7-8):787–794. doi:10.1016/s0736-5748(98)00088-4
Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H (1996) Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer’s disease. Neuroreport 7(18):2925–2928
Goedert M, Fine A, Hunt SP, Ullrich A (1986) Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in Alzheimer’s disease. Brain Res 387(1):85–92
Hock C, Heese K, Muller-Spahn F, Hulette C, Rosenberg C, Otten U (1998) Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer’s disease. Neurosci Lett 241(2-3):151–154. doi:10.1016/S0304-3940(98)00019-6
Cui B, Wu C, Chen L, Ramirez A, Bearer EL, Li WP, Mobley WC, Chu S (2007) One at a time, live tracking of NGF axonal transport using quantum dots. Proc Natl Acad Sci U S A 104(34):13666–13671. doi:10.1073/pnas.0706192104
Cooper JD, Salehi A, Delcroix JD et al (2001) Failed retrograde transport of NGF in a mouse model of Down’s syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci U S A 98(18):10439–10444. doi:10.1073/pnas.181219298
Mufson EJ, Conner JM, Kordower JH (1995) Nerve growth factor in Alzheimer’s disease: defective retrograde transport to nucleus basalis. Neuroreport 6(7):1063–1066
Schindowski K, Belarbi K, Buee L (2008) Neurotrophic factors in Alzheimer’s disease: role of axonal transport. Genes Brain Behav 7(Suppl 1 (s1)):43–56. doi:10.1111/j.1601-183X.2007.00378.x
Peng S, Wuu J, Mufson EJ, Fahnestock M (2004) Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol 63(6):641–649
Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron 7(5):695–702
Holsinger RM, Schnarr J, Henry P, Castelo VT, Fahnestock M (2000) Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer’s disease. Brain Res Mol Brain Res 76(2):347–354
Connor B, Young D, Yan Q, Faull RLM, Synek B, Dragunow M (1997) Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Mol Brain Res 49(1-2):71–81. doi:10.1016/S0169-328x(97)00125-3
Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, Blanco R, Tolosa E, Marti E (1999) BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol 58(7):729–739
Durany N, Michel T, Kurt J, Cruz-Sanchez FF, Cervos-Navarro J, Riederer P (2000) Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer’s disease brains. Int J Dev Neurosci 18(8):807–813. doi:10.1016/S0736-5748(00)00046-0
Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ (2002) Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 70(3):462–473. doi:10.1002/jnr.10351
Michalski B, Fahnestock M (2003) Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer’s disease. Mol Brain Res 111(1-2):148–154. doi:10.1016/S0169-328x(03)00003-2
Peng S, Wuu J, Mufson EJ, Fahnestock M (2005) Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem 93(6):1412–1421. doi:10.1111/j.1471-4159.2005.03135.x
Laske C, Stransky E, Leyhe T et al (2007) BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 41(5):387–394. doi:10.1016/j.jpsychires.2006.01.014
Kunugi H, Ueki A, Otsuka M et al (2001) A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer’s disease. Mol Psychiatry 6(1):83–86
Egan MF, Kojima M, Callicott JH et al (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2):257–269. doi:10.1016/S0092-8674(03)00035-7
Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, Lee FS (2004) Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 24(18):4401–4411. doi:10.1523/jneurosci.0348-04.2004
Chen ZY, Ieraci A, Teng H et al (2005) Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway. J Neurosci 25(26):6156–6166. doi:10.1523/jneurosci.1017-05.2005
Bueller JA, Aftab M, Sen S, Gomez-Hassan D, Burmeister M, Zubieta JK (2006) BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry 59(9):812–815. doi:10.1016/j.biopsych.2005.09.022
Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, Weinberger DR (2003) Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 23(17):6690–6694
Nagata T, Shinagawa S, Nukariya K, Yamada H, Nakayama K (2012) Association between BDNF polymorphism (Val66Met) and executive function in patients with amnestic mild cognitive impairment or mild Alzheimer disease. Dement Geriatr Cogn Disord 33(4):266–272. doi:10.1159/000339358
Tsai SJ, Hong CJ, Liu HC, Liu TY, Hsu LE, Lin CH (2004) Association analysis of brain-derived neurotrophic factor Val66Met polymorphisms with Alzheimer’s disease and age of onset. Neuropsychobiology 49(1):10–12. doi:10.1159/000075332
Fukumoto N, Fujii T, Combarros O et al (2010) Sexually dimorphic effect of the Val66Met polymorphism of BDNF on susceptibility to Alzheimer’s disease: new data and meta-analysis. Am J Med Genet B Neuropsychiatr Genet 153b(1):235–242. doi:10.1002/ajmg.b.30986
Ventriglia M, Bocchio Chiavetto L, Benussi L, Binetti G, Zanetti O, Riva MA, Gennarelli M (2002) Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer’s disease. Mol Psychiatry 7(2):136–137. doi:10.1038/sj.mp.4000952
Bagnoli S, Nacmias B, Tedde A et al (2004) Brain-derived neurotrophic factor genetic variants are not susceptibility factors to Alzheimer’s disease in Italy. Ann Neurol 55(3):447–448. doi:10.1002/ana.10842
Combarros O, Infante J, Llorca J, Berciano J (2004) Polymorphism at codon 66 of the brain-derived neurotrophic factor gene is not associated with sporadic Alzheimer’s disease. Dement Geriatr Cogn Disord 18(1):55–58. doi:10.1159/000077736
Nishimura M, Kuno S, Kaji R, Kawakami H (2005) Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer’s disease, Parkinson’s disease, and multiple system atrophy. Mov Disord 20(8):1031–1033. doi:10.1002/mds.20491
Zhang H, Ozbay F, Lappalainen J et al (2006) Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer’s disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependence. Am J Med Genet B Neuropsychiatr Genet 141b(4):387–393. doi:10.1002/ajmg.b.30332
Ji H, Dai D, Wang Y et al (2015) Association of BDNF and BCHE with Alzheimer’s disease: meta-analysis based on 56 genetic case-control studies of 12,563 cases and 12,622 controls. Exp Ther Med 9(5):1831–1840. doi:10.3892/etm.2015.2327
Lin Y, Cheng S, Xie Z, Zhang D (2014) Association of rs6265 and rs2030324 polymorphisms in brain-derived neurotrophic factor gene with Alzheimer’s disease: a meta-analysis. PLoS One 9(4), e94961. doi:10.1371/journal.pone.0094961
Voineskos AN, Lerch JP, Felsky D et al (2011) The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease. Arch Gen Psychiatry 68(2):198–206. doi:10.1001/archgenpsychiatry.2010.194
Notaras M, Hill R, van den Buuse M (2015) The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy. Mol Psychiatry 20(8):916–930. doi:10.1038/mp.2015.27
Borroni B, Grassi M, Archetti S et al (2009) BDNF genetic variations increase the risk of Alzheimer’s disease-related depression. J Alzheimers Dis 18(4):867–875. doi:10.3233/jad-2009-1191
Borroni B, Archetti S, Costanzi C et al (2009) Role of BDNF Val66Met functional polymorphism in Alzheimer’s disease-related depression. Neurobiol Aging 30(9):1406–1412. doi:10.1016/j.neurobiolaging.2007.11.023
Numata S, Ueno S, Iga J et al (2006) Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms. Neurosci Lett 401(1-2):1–5. doi:10.1016/j.neulet.2006.02.054
Chen ZY, Jing D, Bath KG et al (2006) Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 314(5796):140–143. doi:10.1126/science.1129663
Bian JT, Zhang JW, Zhang ZX, Zhao HL (2005) Association analysis of brain-derived neurotrophic factor (BDNF) gene 196 A/G polymorphism with Alzheimer’s disease (AD) in mainland Chinese. Neurosci Lett 387(1):11–16. doi:10.1016/j.neulet.2005.07.009
Shintani A, Ono Y, Kaisho Y, Igarashi K (1992) Characterization of the 5′-flanking region of the human brain-derived neurotrophic factor gene. Biochem Biophys Res Commun 182(1):325–332
Riemenschneider M, Schwarz S, Wagenpfeil S, Diehl J, Muller U, Forstl H, Kurz A (2002) A polymorphism of the brain-derived neurotrophic factor (BDNF) is associated with Alzheimer’s disease in patients lacking the Apolipoprotein E epsilon4 allele. Mol Psychiatry 7(7):782–785. doi:10.1038/sj.mp.4001073
Diniz BS, Teixeira AL (2011) Brain-derived neurotrophic factor and Alzheimer’s disease: physiopathology and beyond. Neuromol Med 13(4):217–222. doi:10.1007/s12017-011-8154-x
Olson LE, Roper RJ, Baxter LL, Carlson EJ, Epstein CJ, Reeves RH (2004) Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes. Dev Dyn 230(3):581–589. doi:10.1002/dvdy.20079
Mann DMA (1988) The pathological association between down syndrome and Alzheimer-disease. Mech Ageing Dev 43(2):99–136. doi:10.1016/0047-6374(88)90041-3
Salehi A, Delcroix JD, Belichenko PV et al (2006) Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51(1):29–42. doi:10.1016/j.neuron.2006.05.022
Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer’s disease and transgenic models. Annu Rev Neurosci 21(1):479–505. doi:10.1146/annurev.neuro.21.1.479
Hardy J (1997) Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci 20(4):154–159. doi:10.1016/S0166-2236(96)01030-2
Ari C, Borysov SI, Wu J, Padmanabhan J, Potter H (2014) Alzheimer amyloid beta inhibition of Eg5/kinesin 5 reduces neurotrophin and/or transmitter receptor function. Neurobiol Aging 35(8):1839–1849. doi:10.1016/j.neurobiolaging.2014.02.006
Heese K, Inoue N, Nagai Y, Sawada T (2004) APP, NGF & the ‘Sunday-driver’ in a trolley on the road. Restor Neurol Neurosci 22(2):131–136
Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VMY (1993) Abnormal tau phosphorylation at Ser396 in alzheimer’s disease recapitulates development and contributes to reduced microtubule binding. Neuron 10(6):1089–1099. doi:10.1016/0896-6273(93)90057-x
Ahlijanian MK, Barrezueta NX, Williams RD et al (2000) Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci U S A 97(6):2910–2915. doi:10.1073/pnas.040577797
Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E (2003) Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24(8):1079–1085. doi:10.1016/j.neurobiolaging.2003.04.007
Terwel D, Dewachter I, Van Leuven F (2002) Axonal transport, tau protein, and neurodegeneration in Alzheimer’s disease. Neuromolecular Med 2(2):151–165. doi:10.1385/NMM:2:2:151
Cowan CM, Bossing T, Page A, Shepherd D, Mudher A (2010) Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. Acta Neuropathol 120(5):593–604. doi:10.1007/s00401-010-0716-8
Shemesh OA, Erez H, Ginzburg I, Spira ME (2008) Tau-induced traffic jams reflect organelles accumulation at points of microtubule polar mismatching. Traffic 9(4):458–471. doi:10.1111/j.1600-0854.2007.00695.x
Butzlaff M, Hannan SB, Karsten P et al (2015) Impaired retrograde transport by the Dynein/Dynactin complex contributes to Tau-induced toxicity. Hum Mol Genet 24(13):3623–3637. doi:10.1093/hmg/ddv107
Dixit R, Ross JL, Goldman YE, Holzbaur EL (2008) Differential regulation of dynein and kinesin motor proteins by tau. Science 319(5866):1086–1089. doi:10.1126/science.1152993
Seiler M, Schwab ME (1984) Specific retrograde transport of nerve growth factor (NGF) from neocortex to nucleus basalis in the rat. Brain Res 300(1):33–39. doi:10.1016/0006-8993(84)91338-6
Merighi A (2002) Costorage and coexistence of neuropeptides in the mammalian CNS. Prog Neurobiol 66(3):161–190. doi:10.1016/S0301-0082(01)00031-4
Saito N, Okada Y, Noda Y, Kinoshita Y, Kondo S, Hirokawa N (1997) KIFC2 is a novel neuron-specific C-terminal type kinesin superfamily motor for dendritic transport of multivesicular body-like organelles. Neuron 18(3):425–438. doi:10.1016/S0896-6273(00)81243-X
Wakana Y, Villeneuve J, van Galen J, Cruz-Garcia D, Tagaya M, Malhotra V (2013) Kinesin-5/Eg5 is important for transport of CARTS from the trans-Golgi network to the cell surface. J Cell Biol 202(2):241–250. doi:10.1083/jcb.201303163
Bradshaw RA, Pundavela J, Biarc J, Chalkley RJ, Burlingame AL, Hondermarck H (2015) NGF and ProNGF: regulation of neuronal and neoplastic responses through receptor signaling. Adv Biol Regul 58:16–27. doi:10.1016/j.jbior.2014.11.003
Garzon DJ, Fahnestock M (2007) Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci 27(10):2628–2635. doi:10.1523/JNEUROSCI.5053-06.2007
Mufson EJ, Lavine N, Jaffar S, Kordower JH, Quirion R, Saragovi HU (1997) Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer’s disease. Exp Neurol 146(1):91–103. doi:10.1006/exnr.1997.6504
Mufson EJ, Li JM, Sobreviela T, Kordower JH (1996) Decreased trkA gene expression within basal forebrain neurons in Alzheimer’s disease. Neuroreport 8(1):25–29. doi:10.1097/00001756-199612200-00006
Mufson EJ, Ma SY, Cochran EJ, Bennett DA, Beckett LA, Jaffar S, Saragovi HU, Kordower JH (2000) Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer’s disease. J Comp Neurol 427(1):19–30. doi:10.1002/1096-9861(20001106)427:1<19::AID-CNE2>3.0.CO;2-A
Ginsberg SD, Che S, Wuu J, Counts SE, Mufson EJ (2006) Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer’s disease. J Neurochem 97(2):475–487. doi:10.1111/j.1471-4159.2006.03764.x
Chu YP, Cochran EJ, Bennett DA, Mufson EJ, Kordower JH (2001) Down-regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer’s disease. J Comp Neurol 437(3):296–307. doi:10.1002/Cne.1284
Allen SJ, Wilcock GK, Dawbarn D (1999) Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer’s disease. Biochem Biophys Res Commun 264(3):648–651. doi:10.1006/bbrc.1999.1561
Davie CA (2008) A review of Parkinson’s disease. Br Med Bull 86(1):109–127. doi:10.1093/bmb/ldn013
Doherty KM, van de Warrenburg BP, Peralta MC, Silveira-Moriyama L, Azulay JP, Gershanik OS, Bloem BR (2011) Postural deformities in Parkinson’s disease. Lancet Neurol 10(6):538–549. doi:10.1016/S1474-4422(11)70067-9
Emre M (2003) Dementia associated with Parkinson’s disease. Lancet Neurol 2(4):229–237. doi:10.1016/S1474-4422(03)00351-X
Horimoto Y, Matsumoto M, Nakazawa H et al (2003) Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson’s disease with dementia. J Neurol Sci 216(1):105–108
Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51(6):745–752. doi:10.1136/jnnp.51.6.745
Shulman JM, De Jager PL, Feany MB (2011) Parkinson’s disease: genetics and pathogenesis. Annu Rev Pathol 6(1):193–222. doi:10.1146/annurev-pathol-011110-130242
Martin I, Dawson VL, Dawson TM (2011) Recent advances in the genetics of Parkinson’s disease. Annu Rev Genomics Hum Genet 12:301–325. doi:10.1146/annurev-genom-082410-101440
Trinh J, Farrer M (2013) Advances in the genetics of Parkinson disease. Nat Rev Neurol 9(8):445–454. doi:10.1038/nrneurol.2013.132
Irwin DJ, Lee VM, Trojanowski JQ (2013) Parkinson’s disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci 14(9):626–636. doi:10.1038/nrn3549
Charlesworth G, Gandhi S, Bras JM et al (2012) Tau acts as an independent genetic risk factor in pathologically proven PD. Neurobiol Aging 33(4):838.e7–838.e11. doi:10.1016/j.neurobiolaging.2011.11.001
Chauhan NB, Siegel GJ, Lee JM (2001) Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson’s disease brain. J Chem Neuroanat 21(4):277–288. doi:10.1016/S0891-0618(01)00115-6
Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T (1999) Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson’s disease. Neurosci Lett 270(1):45–48
Parain K, Murer MG, Yan Q, Faucheux B, Agid Y, Hirsch E, Raisman-Vozari R (1999) Reduced expression of brain-derived neurotrophic factor protein in Parkinson’s disease substantia nigra. Neuroreport 10(3):557–561
Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, Donnan GA (2000) Reduced BDNF mRNA expression in the Parkinson’s disease substantia nigra. Exp Neurol 166(1):127–135. doi:10.1006/exnr.2000.7483
Baquet ZC, Bickford PC, Jones KR (2005) Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 25(26):6251–6259. doi:10.1523/JNEUROSCI.4601-04.2005
Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P (2001) BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411(6833):86–89. doi:10.1038/35075076
Guillin O, Griffon N, Bezard E, Leriche L, Diaz J, Gross C, Sokoloff P (2003) Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson’s disease. Eur J Pharmacol 480(1-3):89–95. doi:10.1016/j.ejphar.2003.08.096
Du X, Stull ND, Iacovitti L (1995) Brain-derived neurotrophic factor works coordinately with partner molecules to initiate tyrosine hydroxylase expression in striatal neurons. Brain Res 680(1-2):229–233. doi:10.1016/0006-8993(95)00215-C
Peng C, Aron L, Klein R, Li M, Wurst W, Prakash N, Le W (2011) Pitx3 is a critical mediator of GDNF-induced BDNF expression in nigrostriatal dopaminergic neurons. J Neurosci 31(36):12802–12815. doi:10.1523/JNEUROSCI.0898-11.2011
Yuan Y, Sun J, Zhao M, Hu J, Wang X, Du G, Chen NH (2010) Overexpression of alpha-synuclein down-regulates BDNF expression. Cell Mol Neurobiol 30(6):939–946. doi:10.1007/s10571-010-9523-y
Chu Y, Morfini GA, Langhamer LB, He Y, Brady ST, Kordower JH (2012) Alterations in axonal transport motor proteins in sporadic and experimental Parkinson’s disease. Brain 135(Pt 7):2058–2073. doi:10.1093/brain/aws133
Lamberts JT, Hildebrandt EN, Brundin P (2015) Spreading of alpha-synuclein in the face of axonal transport deficits in Parkinson’s disease: a speculative synthesis. Neurobiol Dis 77:276–283. doi:10.1016/j.nbd.2014.07.002
Chung CY, Koprich JB, Siddiqi H, Isacson O (2009) Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci 29(11):3365–3373. doi:10.1523/JNEUROSCI.5427-08.2009
Prots I, Veber V, Brey S, Campioni S, Buder K, Riek R, Bohm KJ, Winner B (2013) alpha-Synuclein oligomers impair neuronal microtubule-kinesin interplay. J Biol Chem 288(30):21742–21754. doi:10.1074/jbc.M113.451815
Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389(6653):856–860. doi:10.1038/39885
Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S (1997) Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci 17(7):2295–2313
Zhou XF, Rush RA (1996) Endogenous brain-derived neurotrophic factor is anterogradely transported in primary sensory neurons. Neuroscience 74(4):945–951. doi:10.1016/S0306-4522(96)00237-0
de Wert G, Mummery C (2003) Human embryonic stem cells: research, ethics and policy. Hum Reprod 18(4):672–682
Hug K (2006) Therapeutic perspectives of human embryonic stem cell research versus the moral status of a human embryo--does one have to be compromised for the other? Medicina (Kaunas) 42(2):107–114
Hug K, Hermeren G (2011) Do we still need human embryonic stem cells for stem cell-based therapies? Epistemic and ethical aspects. Stem Cell Rev 7(4):761–774. doi:10.1007/s12015-011-9257-3
Nussbaum J, Minami E, Laflamme MA et al (2007) Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J 21(7):1345–1357. doi:10.1096/fj.06-6769com
Wang Q, Matsumoto Y, Shindo T et al (2006) Neural stem cells transplantation in cortex in a mouse model of Alzheimer’s disease. J Med Investig 53(1-2):61–69
Lindvall O, Kokaia Z (2006) Stem cells for the treatment of neurological disorders. Nature 441(7097):1094–1096. doi:10.1038/nature04960
Bissonnette CJ, Lyass L, Bhattacharyya BJ, Belmadani A, Miller RJ, Kessler JA (2011) The controlled generation of functional basal forebrain cholinergic neurons from human embryonic stem cells. Stem Cells 29(5):802–811. doi:10.1002/stem.626
Yue W, Li Y, Zhang T et al (2015) ESC-derived basal forebrain cholinergic neurons ameliorate the cognitive symptoms associated with Alzheimer’s disease in mouse models. Stem Cell Rep 5(5):776–790. doi:10.1016/j.stemcr.2015.09.010
Oakley H, Cole SL, Logan S et al (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26(40):10129–10140. doi:10.1523/JNEUROSCI.1202-06.2006
Kimura R, Ohno M (2009) Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol Dis 33(2):229–235. doi:10.1016/j.nbd.2008.10.006
Blurton-Jones M, Kitazawa M, Martinez-Coria H et al (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A 106(32):13594–13599. doi:10.1073/pnas.0901402106
Ager RR, Davis JL, Agazaryan A, Benavente F, Poon WW, LaFerla FM, Blurton-Jones M (2015) Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer’s disease and neuronal loss. Hippocampus 25(7):813–826. doi:10.1002/hipo.22405
Ben-Hur T, Idelson M, Khaner H, Pera M, Reinhartz E, Itzik A, Reubinoff BE (2004) Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells 22(7):1246–1255. doi:10.1634/stemcells.2004-0094
Bjorklund LM, Sanchez-Pernaute R, Chung S et al (2002) Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A 99(4):2344–2349. doi:10.1073/pnas.022438099
Barberi T, Klivenyi P, Calingasan NY et al (2003) Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol 21(10):1200–1207. doi:10.1038/nbt870
Takagi Y, Takahashi J, Saiki H et al (2005) Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 115(1):102–109. doi:10.1172/JCI21137
Steinbeck JA, Choi SJ, Mrejeru A, Ganat Y, Deisseroth K, Sulzer D, Mosharov EV, Studer L (2015) Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson’s disease model. Nat Biotechnol 33(2):204–209. doi:10.1038/nbt.3124
Sterniczuk R, Antle MC, Laferla FM, Dyck RH (2010) Characterization of the 3xTg-AD mouse model of Alzheimer’s disease: part 2. Behavioral and cognitive changes. Brain Res 1348:149–155. doi:10.1016/j.brainres.2010.06.011
Yeung ST, Myczek K, Kang AP, Chabrier MA, Baglietto-Vargas D, Laferla FM (2014) Impact of hippocampal neuronal ablation on neurogenesis and cognition in the aged brain. Neuroscience 259:214–222. doi:10.1016/j.neuroscience.2013.11.054
Lee P, Morley G, Huang Q et al (1998) Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A 95(19):11371–11376
McGill TJ, Cottam B, Lu B et al (2012) Transplantation of human central nervous system stem cells—neuroprotection in retinal degeneration. Eur J Neurosci 35(3):468–477. doi:10.1111/j.1460-9568.2011.07970.x
Heese K, Low JW, Inoue N (2006) Nerve growth factor, neural stem cells and Alzheimer’s disease. Neurosignals 15(1):1–12. doi:10.1159/000094383
Scardigli R, Capelli P, Vignone D et al (2014) Neutralization of nerve growth factor impairs proliferation and differentiation of adult neural progenitors in the subventricular zone. Stem Cells 32(9):2516–2528. doi:10.1002/stem.1744
Nagahara AH, Merrill DA, Coppola G et al (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med 15(3):331–337. doi:10.1038/nm.1912
Nagahara AH, Mateling M, Kovacs I et al (2013) Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci 33(39):15596–15602. doi:10.1523/JNEUROSCI.5195-12.2013
Svendsen CN, Caldwell MA, Shen J, ter Borg MG, Rosser AE, Tyers P, Karmiol S, Dunnett SB (1997) Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson’s disease. Exp Neurol 148(1):135–146. doi:10.1006/exnr.1997.6634
Lindvall O (2015) Treatment of Parkinson’s disease using cell transplantation. Philos Trans R Soc Lond B Biol Sci 370(1680):20140370. doi:10.1098/rstb.2014.0370
Mimeault M, Batra SK (2006) Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells 24(11):2319–2345. doi:10.1634/stemcells.2006-0066
Redmond DE Jr, Bjugstad KB, Teng YD et al (2007) Behavioral improvement in a primate Parkinson’s model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci U S A 104(29):12175–12180. doi:10.1073/pnas.0704091104
Gu S, Huang H, Bi J, Yao Y, Wen T (2009) Combined treatment of neurotrophin-3 gene and neural stem cells is ameliorative to behavior recovery of Parkinson’s disease rat model. Brain Res 1257:1–9. doi:10.1016/j.brainres.2008.12.016
Daviaud N, Garbayo E, Sindji L, Martinez-Serrano A, Schiller PC, Montero-Menei CN (2015) Survival, differentiation, and neuroprotective mechanisms of human stem cells complexed with neurotrophin-3-releasing pharmacologically active microcarriers in an ex vivo model of Parkinson’s disease. Stem Cells Transl Med 4(6):670–684. doi:10.5966/sctm.2014-0139
Daviaud N, Garbayo E, Lautram N, Franconi F, Lemaire L, Perez-Pinzon M, Montero-Menei CN (2014) Modeling nigrostriatal degeneration in organotypic cultures, a new ex vivo model of Parkinson’s disease. Neuroscience 256:10–22. doi:10.1016/j.neuroscience.2013.10.021
Giteau A, Venier-Julienne MC, Marchal S, Courthaudon JL, Sergent M, Montero-Menei C, Verdier JM, Benoit JP (2008) Reversible protein precipitation to ensure stability during encapsulation within PLGA microspheres. Eur J Pharm Biopharm 70(1):127–136. doi:10.1016/j.ejpb.2008.03.006
Delcroix GJ, Garbayo E, Sindji L, Thomas O, Vanpouille-Box C, Schiller PC, Montero-Menei CN (2011) The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats. Biomaterials 32(6):1560–1573. doi:10.1016/j.biomaterials.2010.10.041
Tatard VM, Sindji L, Branton JG, Aubert-Pouessel A, Colleau J, Benoit JP, Montero-Menei CN (2007) Pharmacologically active microcarriers releasing glial cell line—derived neurotrophic factor: Survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats. Biomaterials 28(11):1978–1988. doi:10.1016/j.biomaterials.2006.12.021
Danielyan L, Schafer R, von Ameln-Mayerhofer A et al (2011) Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res 14(1):3–16. doi:10.1089/rej.2010.1130
Tfilin M, Sudai E, Merenlender A, Gispan I, Yadid G, Turgeman G (2010) Mesenchymal stem cells increase hippocampal neurogenesis and counteract depressive-like behavior. Mol Psychiatry 15(12):1164–1175. doi:10.1038/mp.2009.110
Nguyen MD, Julien JP, Rivest S (2002) Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 3(3):216–227. doi:10.1038/nrn752
Turgeman G (2015) The therapeutic potential of mesenchymal stem cells in Alzheimer’s disease: converging mechanisms. Neural Regen Res 10(5):698–699. doi:10.4103/1673-5374.156953
Takata K, Kitamura Y, Yanagisawa D et al (2007) Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats. FEBS Lett 581(3):475–478. doi:10.1016/j.febslet.2007.01.009
Lee HJ, Lee JK, Lee H et al (2012) Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer’s disease mouse model through modulation of neuroinflammation. Neurobiol Aging 33(3):588–602. doi:10.1016/j.neurobiolaging.2010.03.024
Lee JK, Jin HK, Bae JS (2009) Bone marrow-derived mesenchymal stem cells reduce brain amyloid-beta deposition and accelerate the activation of microglia in an acutely induced Alzheimer’s disease mouse model. Neurosci Lett 450(2):136–141. doi:10.1016/j.neulet.2008.11.059
Lee JK, Schuchman EH, Jin HK, Bae JS (2012) Soluble CCL5 derived from bone marrow-derived mesenchymal stem cells and activated by amyloid beta ameliorates Alzheimer’s disease in mice by recruiting bone marrow-induced microglia immune responses. Stem Cells 30(7):1544–1555. doi:10.1002/stem.1125
Simard AR, Soulet D, Gowing G, Julien JP, Rivest S (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron 49(4):489–502. doi:10.1016/j.neuron.2006.01.022
Kopen GC, Prockop DJ, Phinney DG (1999) Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A 96(19):10711–10716
Krabbe C, Zimmer J, Meyer M (2005) Neural transdifferentiation of mesenchymal stem cells--a critical review. APMIS 113(11-12):831–844. doi:10.1111/j.1600-0463.2005.apm_3061.x
Verkhratsky A, Zorec R, Rodriguez JJ, Parpura V (2016) Astroglia dynamics in ageing and Alzheimer’s disease. Curr Opin Pharmacol 26:74–79. doi:10.1016/j.coph.2015.09.011
Vincent AJ, Gasperini R, Foa L, Small DH (2010) Astrocytes in Alzheimer’s disease: emerging roles in calcium dysregulation and synaptic plasticity. J Alzheimers Dis 22(3):699–714. doi:10.3233/JAD-2010-101089
Savonenko A, Xu GM, Melnikova T et al (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer’s disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18(3):602–617. doi:10.1016/j.nbd.2004.10.022
Pihlaja R, Koistinaho J, Malm T, Sikkila H, Vainio S, Koistinaho M (2008) Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer’s disease. Glia 56(2):154–163. doi:10.1002/glia.20599
Song MS, Learman CR, Ahn KC, Baker GB, Kippe J, Field EM, Dunbar GL (2015) In vitro validation of effects of BDNF-expressing mesenchymal stem cells on neurodegeneration in primary cultured neurons of APP/PS1 mice. Neuroscience 307:37–50. doi:10.1016/j.neuroscience.2015.08.011
Zilka N, Zilkova M, Kazmerova Z, Sarissky M, Cigankova V, Novak M (2011) Mesenchymal stem cells rescue the Alzheimer’s disease cell model from cell death induced by misfolded truncated tau. Neuroscience 193:330–337. doi:10.1016/j.neuroscience.2011.06.088
Gengler S, Hamilton A, Holscher C (2010) Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer’s disease is impaired in old but not young mice. PLoS One 5(3), e9764. doi:10.1371/journal.pone.0009764
Politis M, Lindvall O (2012) Clinical application of stem cell therapy in Parkinson’s disease. BMC Med 10(1):1. doi:10.1186/1741-7015-10-1
Uccelli A, Laroni A, Freedman MS (2011) Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 10(7):649–656. doi:10.1016/S1474-4422(11)70121-1
Cova L, Armentero MT, Zennaro E et al (2010) Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson’s disease. Brain Res 1311:12–27. doi:10.1016/j.brainres.2009.11.041
Bouchez G, Sensebe L, Vourc’h P et al (2008) Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson’s disease. Neurochem Int 52(7):1332–1342. doi:10.1016/j.neuint.2008.02.003
Danielyan L, Beer-Hammer S, Stolzing A et al (2014) Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer’s and Parkinson’s disease. Cell Transplant 23(Suppl 1):S123–S139. doi:10.3727/096368914X684970
Suzuki S, Kawamata J, Iwahara N et al (2015) Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats. Neurosci Lett 584:276–281. doi:10.1016/j.neulet.2014.10.039
Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S, Melamed E, Offen D (2009) Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson’s disease. J Mol Neurosci 39(1-2):199–210. doi:10.1007/s12031-008-9166-3
McCoy MK, Martinez TN, Ruhn KA, Wrage PC, Keefer EW, Botterman BR, Tansey KE, Tansey MG (2008) Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson’s disease. Exp Neurol 210(1):14–29. doi:10.1016/j.expneurol.2007.10.011
Teixeira FG, Carvalho MM, Sousa N, Salgado AJ (2013) Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration? Cell Mol Life Sci 70(20):3871–3882. doi:10.1007/s00018-013-1290-8
Franco Lambert AP, Fraga Zandonai A, Bonatto D, Cantarelli Machado D, Pegas Henriques JA (2009) Differentiation of human adipose-derived adult stem cells into neuronal tissue: does it work? Differentiation 77(3):221–228. doi:10.1016/j.diff.2008.10.016
Yagi T, Ito D, Okada Y et al (2011) Modeling familial Alzheimer’s disease with induced pluripotent stem cells. Hum Mol Genet 20(23):4530–4539. doi:10.1093/hmg/ddr394
Young JE, Goldstein LS (2012) Alzheimer’s disease in a dish: promises and challenges of human stem cell models. Hum Mol Genet 21(R1):R82–R89. doi:10.1093/hmg/dds319
Scheuner D, Eckman C, Jensen M et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 2(8):864–870
Israel MA, Yuan SH, Bardy C et al (2012) Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature 482(7384):216–220. doi:10.1038/nature10821
Woodruff G, Young JE, Martinez FJ et al (2013) The presenilin-1 DeltaE9 mutation results in reduced gamma-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. Cell Rep 5(4):974–985. doi:10.1016/j.celrep.2013.10.018
Ooi L, Sidhu K, Poljak A, Sutherland G, O’Connor MD, Sachdev P, Munch G (2013) Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer’s disease. J Neural Transm (Vienna) 120(1):103–111. doi:10.1007/s00702-012-0839-2
Wojda U, Kuznicki J (2013) Alzheimer’s disease modeling: ups, downs, and perspectives for human induced pluripotent stem cells. J Alzheimers Dis 34(3):563–588. doi:10.3233/JAD-121984
Hotta A, Yamanaka S (2015) From genomics to gene therapy: induced pluripotent stem cells meet genome editing. Annu Rev Genet 49:47–70. doi:10.1146/annurev-genet-112414-054926
Kime C, Mandegar MA, Srivastava D, Yamanaka S, Conklin BR, Rand TA (2016) Efficient CRISPR/Cas9-based genome engineering in human pluripotent stem cells. Curr Protoc Hum Genet 88:21.4.1–21.4.23. doi:10.1002/0471142905.hg2104s88
Watson LM, Wong MM, Becker EB (2015) Induced pluripotent stem cell technology for modelling and therapy of cerebellar ataxia. Open Biol 5(7):150056. doi:10.1098/rsob.150056
Hunsberger JG, Rao M, Kurtzberg J et al (2015) Accelerating stem cell trials for Alzheimer’s disease. Lancet Neurol. doi:10.1016/S1474-4422(15)00332-4
Soldner F, Laganiere J, Cheng AW et al (2011) Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146(2):318–331. doi:10.1016/j.cell.2011.06.019
Hockemeyer D, Wang H, Kiani S et al (2011) Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29(8):731–734. doi:10.1038/nbt.1927
Sander JD, Cade L, Khayter C, Reyon D, Peterson RT, Joung JK, Yeh JR (2011) Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nat Biotechnol 29(8):697–698. doi:10.1038/nbt.1934
Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (2013) RNA-guided human genome engineering via Cas9. Science 339(6121):823–826. doi:10.1126/science.1232033
Kim D, Bae S, Park J et al (2015) Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods 12(3):237–243. doi:10.1038/nmeth.3284, 231 p following 243
Gaj T, Gersbach CA, Barbas CF 3rd (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31(7):397–405. doi:10.1016/j.tibtech.2013.04.004
Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD (2010) Genome editing with engineered zinc finger nucleases. Nat Rev Genet 11(9):636–646. doi:10.1038/nrg2842
Joung JK, Sander JD (2013) TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14(1):49–55. doi:10.1038/nrm3486
Sander JD, Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32(4):347–355. doi:10.1038/nbt.2842
Dominguez AA, Lim WA, Qi LS (2016) Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat Rev Mol Cell Biol 17(1):5–15. doi:10.1038/nrm.2015.2
Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157(6):1262–1278. doi:10.1016/j.cell.2014.05.010
Doudna JA, Charpentier E (2014) Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346(6213):1258096. doi:10.1126/science.1258096
Beevers JE, Caffrey TM, Wade-Martins R (2013) Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson’s disease. Biochem Soc Trans 41(6):1503–1508. doi:10.1042/BST20130194
Byers B, Cord B, Nguyen HN et al (2011) SNCA triplication Parkinson’s patient’s iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress. PLoS One 6(11), e26159. doi:10.1371/journal.pone.0026159
Devine MJ, Ryten M, Vodicka P et al (2011) Parkinson’s disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat Commun 2:440. doi:10.1038/ncomms1453
Jiang H, Ren Y, Yuen EY et al (2012) Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat Commun 3:668. doi:10.1038/ncomms1669
Byers B, Lee HL, Reijo Pera R (2012) Modeling Parkinson’s disease using induced pluripotent stem cells. Curr Neurol Neurosci Rep 12(3):237–242. doi:10.1007/s11910-012-0270-y
Nguyen HN, Byers B, Cord B et al (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8(3):267–280. doi:10.1016/j.stem.2011.01.013
Skibinski G, Nakamura K, Cookson MR, Finkbeiner S (2014) Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J Neurosci 34(2):418–433. doi:10.1523/JNEUROSCI.2712-13.2014
Woodard CM, Campos BA, Kuo SH et al (2014) iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson’s disease. Cell Rep 9(4):1173–1182. doi:10.1016/j.celrep.2014.10.023
Winner B, Marchetto MC, Winkler J, Gage FH (2014) Human-induced pluripotent stem cells pave the road for a better understanding of motor neuron disease. Hum Mol Genet 23(R1):R27–R34. doi:10.1093/hmg/ddu205
Marchetto MC, Gage FH (2012) Modeling brain disease in a dish: really? Cell Stem Cell 10(6):642–645. doi:10.1016/j.stem.2012.05.008
Hallett PJ, Deleidi M, Astradsson A et al (2015) Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell 16(3):269–274. doi:10.1016/j.stem.2015.01.018
Sanders LH, Laganiere J, Cooper O et al (2014) LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson’s disease patients: reversal by gene correction. Neurobiol Dis 62:381–386. doi:10.1016/j.nbd.2013.10.013
Blits B, Kirik D, Petry H, Hermening S (2015) Gene therapy for Parkinson’s disease: AAV5-mediated delivery of glial cell line-derived neurotrophic factor (GDNF). In: Bo X, Verhaagen J (eds) Gene delivery and therapy for neurological disorders, vol 98. Neuromethods. Springer New York, pp 67–83. doi:10.1007/978-1-4939-2306-9_3
Kelly MJ, O’Keeffe GW, Sullivan AM (2015) Viral vector delivery of neurotrophic factors for Parkinson’s disease therapy. Expert Rev Mol Med 17, e8. doi:10.1017/erm.2015.6
Muller F-J, Snyder EY, Loring JF (2006) Gene therapy: can neural stem cells deliver? Nat Rev Neurosci 7(1):75–84
Olson L, Nordberg A, von Holst H et al (1992) Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect 4(1):79–95
Eriksdotter Jonhagen M, Nordberg A, Amberla K et al (1998) Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 9(5):246–257
Rafii MS, Baumann TL, Bakay RA et al (2014) A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer’s disease. Alzheimers Dement 10(5):571–581. doi:10.1016/j.jalz.2013.09.004
Tuszynski MH, Thal L, Pay M et al (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11(5):551–555. doi:10.1038/nm1239
Tuszynski MH, Yang JH, Barba D et al (2015) Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease. JAMA Neurol 72(10):1139–1147. doi:10.1001/jamaneurol.2015.1807
Mazzini L, Ferrero I, Luparello V et al (2010) Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. Exp Neurol 223(1):229–237. doi:10.1016/j.expneurol.2009.08.007
Olson L, Backlund EO, Ebendal T et al (1991) Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson’s disease. One-year follow-up of first clinical trial. Arch Neurol 48(4):373–381. doi:10.1001/archneur.1991.00530160037011
Backlund EO, Granberg PO, Hamberger B, Knutsson E, Martensson A, Sedvall G, Seiger A, Olson L (1985) Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 62(2):169–173. doi:10.3171/jns.1985.62.2.0169
Lindvall O, Backlund EO, Farde L et al (1987) Transplantation in Parkinson’s disease: two cases of adrenal medullary grafts to the putamen. Ann Neurol 22(4):457–468. doi:10.1002/ana.410220403
Lapchak PA, Miller PJ, Jiao S (1997) Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 rats. Neuroscience 77(3):745–752
Bowenkamp KE, Lapchak PA, Hoffer BJ, Miller PJ, Bickford PC (1997) Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats. Exp Neurol 145(1):104–117. doi:10.1006/exnr.1997.6436
Maswood N, Grondin R, Zhang Z, Stanford JA, Surgener SP, Gash DM, Gerhardt GA (2002) Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiol Aging 23(5):881–889
Grondin R, Zhang Z, Yi A et al (2002) Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125(Pt 10):2191–2201
Grondin R, Cass WA, Zhang Z, Stanford JA, Gash DM, Gerhardt GA (2003) Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J Neurosci 23(5):1974–1980
Iravani MM, Costa S, Jackson MJ, Tel BC, Cannizzaro C, Pearce RK, Jenner P (2001) GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets. Eur J Neurosci 13(3):597–608
Sun M, Kong L, Wang X, Lu XG, Gao Q, Geller AI (2005) Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson’s disease. Brain Res 1052(2):119–129. doi:10.1016/j.brainres.2005.05.072
Nutt JG, Burchiel KJ, Comella CL et al (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60(1):69–73
Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS (2005) Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 11(7):703–704. doi:10.1038/nm0705-703
Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS (2005) Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 57(2):298–302. doi:10.1002/ana.20374
Slevin JT, Gash DM, Smith CD et al (2006) Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal. Neurosurg Focus 20(5), E1. doi:10.3171/foc.2006.20.5.2
Lang AE, Gill S, Patel NK et al (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59(3):459–466. doi:10.1002/ana.20737
Hovland DN Jr, Boyd RB, Butt MT et al (2007) Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. Toxicol Pathol 35(7):1013–1029. doi:10.1080/01926230701748248
Salvatore MF, Ai Y, Fischer B, Zhang AM, Grondin RC, Zhang Z, Gerhardt GA, Gash DM (2006) Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 202(2):497–505. doi:10.1016/j.expneurol.2006.07.015
Sullivan A, O’Keeffe G (2016) Neurotrophic factor therapy for Parkinson’s disease: past, present and future. Neural Regener Res 11(2):205. doi:10.4103/1673-5374.177710
Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Björklund A (2012) α-synuclein–induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med 4(163):163ra156
Decressac M, Ulusoy A, Mattsson B, Georgievska B, Romero-Ramos M, Kirik D, Bjorklund A (2011) GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson’s disease. Brain 134(Pt 8):2302–2311. doi:10.1093/brain/awr149
Lo Bianco C, Deglon N, Pralong W, Aebischer P (2004) Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson’s disease. Neurobiol Dis 17(2):283–289. doi:10.1016/j.nbd.2004.06.008
Marks WJ Jr, Ostrem JL, Verhagen L et al (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol 7(5):400–408. doi:10.1016/S1474-4422(08)70065-6
Gasmi M, Brandon EP, Herzog CD et al (2007) AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson’s disease. Neurobiol Dis 27(1):67–76. doi:10.1016/j.nbd.2007.04.003
Marks WJ Jr, Bartus RT, Siffert J et al (2010) Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9(12):1164–1172. doi:10.1016/S1474-4422(10)70254-4
Warren Olanow C, Bartus RT, Baumann TL et al (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol 78(2):248–257. doi:10.1002/ana.24436
Lindvall O, Rehncrona S, Brundin P et al (1989) Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 46(6):615–631
Barker RA, Drouin-Ouellet J, Parmar M (2015) Cell-based therapies for Parkinson disease-past insights and future potential. Nat Rev Neurol 11(9):492–503. doi:10.1038/nrneurol.2015.123
Lindvall O (2013) Developing dopaminergic cell therapy for Parkinson’s disease–give up or move forward? Mov Disord 28(3):268–273. doi:10.1002/mds.25378
Kefalopoulou Z, Politis M, Piccini P et al (2014) Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol 71(1):83–87. doi:10.1001/jamaneurol.2013.4749
Freed CR, Greene PE, Breeze RE et al (2001) Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 344(10):710–719. doi:10.1056/NEJM200103083441002
Olanow CW, Goetz CG, Kordower JH et al (2003) A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 54(3):403–414. doi:10.1002/ana.10720
Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med 14(5):504–506. doi:10.1038/nm1747
Li JY, Englund E, Holton JL et al (2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 14(5):501–503. doi:10.1038/nm1746
Mendez I, Vinuela A, Astradsson A et al (2008) Dopamine neurons implanted into people with Parkinson’s disease survive without pathology for 14 years. Nat Med 14(5):507–509. doi:10.1038/nm1752
Kurowska Z, Englund E, Widner H, Lindvall O, Li JY, Brundin P (2011) Signs of degeneration in 12-22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson’s disease. J Parkinsons Dis 1(1):83–92. doi:10.3233/JPD-2011-11004
Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O (2014) Long-term health of dopaminergic neuron transplants in Parkinson’s disease patients. Cell Rep 7(6):1755–1761. doi:10.1016/j.celrep.2014.05.027
Venkataramana NK, Kumar SK, Balaraju S et al (2010) Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson’s disease. Transl Res 155(2):62–70. doi:10.1016/j.trsl.2009.07.006
Venkataramana NK, Pal R, Rao SA et al (2012) Bilateral transplantation of allogenic adult human bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson’s disease: a pilot clinical study. Stem Cells Int 2012:931902. doi:10.1155/2012/931902
Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21(4):583–593. doi:10.1128/CMR.00008-08
Bestor TH (2000) Gene silencing as a threat to the success of gene therapy. J Clin Invest 105(4):409–411. doi:10.1172/JCI9459
Dave UP, Jenkins NA, Copeland NG (2004) Gene therapy insertional mutagenesis insights. Science 303(5656):333. doi:10.1126/science.1091667
Xu CJ, Wang JL, Jin WL (2016) The emerging therapeutic role of NGF in Alzheimer’s disease. Neurochem Res. doi:10.1007/s11064-016-1829-9
Araki R, Uda M, Hoki Y et al (2013) Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 494(7435):100–104. doi:10.1038/nature11807
Morizane A, Doi D, Kikuchi T et al (2013) Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Rep 1(4):283–292. doi:10.1016/j.stemcr.2013.08.007
Zhang L, Fang Y, Lian Y et al (2015) Brain-derived neurotrophic factor ameliorates learning deficits in a rat model of Alzheimer’s disease induced by abeta1-42. PLoS One 10(4), e0122415. doi:10.1371/journal.pone.0122415
Fumagalli F, Racagni G, Riva MA (2005) The expanding role of BDNF: a therapeutic target for Alzheimer’s disease? Pharmacogenomics J 6(1):8–15
Tuszynski MH, Nagahara AH (2016) NGF and BDNF gene therapy for Alzheimer’s disease. In: Tuszynski HM (ed) Translational neuroscience: fundamental approaches for neurological disorders. Springer US, Boston, pp 33–64. doi:10.1007/978-1-4899-7654-3_3
Kaddis FG, Zawada WM, Schaack J, Freed CR (1996) Conditioned medium from aged monkey fibroblasts stably expressing GDNF and BDNF improves survival of embryonic dopamine neurons in vitro. Cell Tissue Res 286(2):241–247. doi:10.1007/s004410050693
Stahl K, Mylonakou MN, Skare O, Amiry-Moghaddam M, Torp R (2011) Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson’s disease. Brain Res 1378:105–118. doi:10.1016/j.brainres.2010.12.090
Kordower JH, Emborg ME, Bloch J et al (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 290(5492):767–773. doi:10.1126/science.290.5492.767
Gash DM, Zhang Z, Ovadia A et al (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380(6571):252–255. doi:10.1038/380252a0
Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Bjorklund A (2012) alpha-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med 4(163):163ra156. doi:10.1126/scitranslmed.3004676
Pearce RK, Costa S, Jenner P, Marsden CD (1999) Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets. J Neural Transm (Vienna) 106(7-8):663–683. doi:10.1007/s007020050188
Tsukahara T, Takeda M, Shimohama S, Ohara O, Hashimoto N (1995) Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 37(4):733–739, discussion 739–741
Park KI, Ourednik J, Ourednik V et al (2002) Global gene and cell replacement strategies via stem cells. Gene Ther 9(10):613–624. doi:10.1038/sj.gt.3301721
Nguyen N, Lee SB, Lee YS, Lee KH, Ahn JY (2009) Neuroprotection by NGF and BDNF against neurotoxin-exerted apoptotic death in neural stem cells are mediated through Trk receptors, activating PI3-kinase and MAPK pathways. Neurochem Res 34(5):942–951. doi:10.1007/s11064-008-9848-9
Park KI, Himes BT, Stieg PE, Tessler A, Fischer I, Snyder EY (2006) Neural stem cells may be uniquely suited for combined gene therapy and cell replacement: Evidence from engraftment of Neurotrophin-3-expressing stem cells in hypoxic-ischemic brain injury. Exp Neurol 199(1):179–190. doi:10.1016/j.expneurol.2006.03.016
Martino G, Pluchino S (2006) The therapeutic potential of neural stem cells. Nat Rev Neurosci 7(5):395–406. doi:10.1038/nrn1908
Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27(3):275–280. doi:10.1038/nbt.1529
Morizane A, Doi D, Kikuchi T, Nishimura K, Takahashi J (2011) Small-molecule inhibitors of bone morphogenic protein and activin/nodal signals promote highly efficient neural induction from human pluripotent stem cells. J Neurosci Res 89(2):117–126. doi:10.1002/jnr.22547
Yuan SH, Martin J, Elia J et al (2011) Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One 6(3), e17540. doi:10.1371/journal.pone.0017540
Han F, Wang W, Chen B et al (2015) Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson’s disease. Cytotherapy 17(5):665–679. doi:10.1016/j.jcyt.2015.02.001
Ben-David U, Benvenisty N (2011) The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 11(4):268–277. doi:10.1038/nrc3034
Kim DS, Lee DR, Kim HS et al (2012) Highly pure and expandable PSA-NCAM-positive neural precursors from human ESC and iPSC-derived neural rosettes. PLoS One 7(7), e39715. doi:10.1371/journal.pone.0039715
Lee MO, Moon SH, Jeong HC et al (2013) Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc Natl Acad Sci U S A 110(35):E3281–E3290. doi:10.1073/pnas.1303669110
Ben-David U, Gan QF, Golan-Lev T et al (2013) Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell 12(2):167–179. doi:10.1016/j.stem.2012.11.015
Lund RJ, Narva E, Lahesmaa R (2012) Genetic and epigenetic stability of human pluripotent stem cells. Nat Rev Genet 13(10):732–744. doi:10.1038/nrg3271
Gore A, Li Z, Fung HL et al (2011) Somatic coding mutations in human induced pluripotent stem cells. Nature 471(7336):63–67. doi:10.1038/nature09805
Cheng L, Hansen NF, Zhao L et al (2012) Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell 10(3):337–344. doi:10.1016/j.stem.2012.01.005
Hawkins RD, Hon GC, Ren B (2010) Next-generation genomics: an integrative approach. Nat Rev Genet 11(7):476–486. doi:10.1038/nrg2795
Kim H, Kim JS (2014) A guide to genome engineering with programmable nucleases. Nat Rev Genet 15(5):321–334. doi:10.1038/nrg3686
Liu J, Gaj T, Yang Y et al (2015) Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells. Nat Protoc 10(11):1842–1859. doi:10.1038/nprot.2015.117
Jo YI, Suresh B, Kim H, Ramakrishna S (2015) CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods. Biochim Biophys Acta 1856(2):234–243. doi:10.1016/j.bbcan.2015.09.003
Sadelain M, Papapetrou EP, Bushman FD (2012) Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer 12(1):51–58. doi:10.1038/nrc3179
Papapetrou EP, Lee G, Malani N et al (2011) Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol 29(1):73–78. doi:10.1038/nbt.1717
Guo L, Yeh ML, Cuzon Carlson VC, Johnson-Venkatesh EM, Yeh HH (2012) Nerve growth factor in the hippocamposeptal system: evidence for activity-dependent anterograde delivery and modulation of synaptic activity. J Neurosci 32(22):7701–7710. doi:10.1523/jneurosci.0028-12.2012
Combarros O, Cortina-Borja M, Smith AD, Lehmann DJ (2009) Epistasis in sporadic Alzheimer’s disease. Neurobiol Aging 30(9):1333–1349. doi:10.1016/j.neurobiolaging.2007.11.027
Acknowledgments
This study was supported by Hanyang University and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2013R1A1A2009178).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Pramanik, S., Sulistio, Y.A. & Heese, K. Neurotrophin Signaling and Stem Cells—Implications for Neurodegenerative Diseases and Stem Cell Therapy. Mol Neurobiol 54, 7401–7459 (2017). https://doi.org/10.1007/s12035-016-0214-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-016-0214-7